<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VFEND- voriconazole tablet, film coated </strong><br>Cardinal Health<br></p></div>
<h1>VFEND<span class="Sup">®</span> I.V.<br>(voriconazole) for Injection<br><br>VFEND<span class="Sup">®</span> Tablets<br> (voriconazole)<br><br>VFEND<span class="Sup">®</span> (voriconazole) for Oral Suspension </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_0d12767c-f0c3-48ed-8477-eba27f6cd84d"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">VFEND<span class="Sup">®</span> (voriconazole), a triazole antifungal agent, is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is:</p>
<div class="Figure"><img alt="Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-01.jpg"></div>
<p>Voriconazole is designated chemically as (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1<span class="Italics">H</span>-1,2,4-triazol-1-yl)-2-butanol with an empirical formula of C<span class="Sub">16</span>H<span class="Sub">14</span>F<span class="Sub">3</span>N<span class="Sub">5</span>O and a molecular weight of 349.3.</p>
<p>Voriconazole drug substance is a white to light-colored powder.</p>
<p>VFEND I.V. is a white lyophilized powder containing nominally 200 mg voriconazole and 3200 mg sulfobutyl ether beta-cyclodextrin sodium in a 30 mL Type I clear glass vial.</p>
<p>VFEND I.V. is intended for administration by intravenous infusion. It is a single-dose, unpreserved product. Vials containing 200 mg lyophilized voriconazole are intended for reconstitution with Water for Injection to produce a solution containing 10 mg/mL VFEND and 160 mg/mL of sulfobutyl ether beta-cyclodextrin sodium. The resultant solution is further diluted prior to administration as an intravenous infusion (see <a href="#i4i_dosage_admin_id_40f5361c-a556-46cc-8ae1-92f7b209c2be">DOSAGE AND ADMINISTRATION</a>).</p>
<p>VFEND Tablets contain 50 mg or 200 mg of voriconazole. The inactive ingredients include lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesium stearate and a coating containing hypromellose, titanium dioxide, lactose monohydrate and triacetin.</p>
<p>VFEND for Oral Suspension is a white to off-white powder providing a white to off-white orange-flavored suspension when reconstituted. Bottles containing 45 g powder for oral suspension are intended for reconstitution with water to produce a suspension containing 40 mg/mL voriconazole. The inactive ingredients include colloidal silicon dioxide, titanium dioxide, xanthan gum, sodium citrate dihydrate, sodium benzoate, anhydrous citric acid, natural orange flavor, and sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a7dc4ff3-a754-4ca9-a070-ff5efd1049b0"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_016edfb3-03a2-44f5-ae47-e204add2666e"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">General Pharmacokinetic Characteristics</p>
<p>The pharmacokinetics of voriconazole have been characterized in healthy subjects, special populations and patients.</p>
<p>The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. The interindividual variability of voriconazole pharmacokinetics is high. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose in healthy subjects from 200 mg Q12h to 300 mg Q12h leads to a 2.5-fold increase in exposure (AUC<span class="Sub">τ</span>), while increasing the intravenous dose from 3 mg/kg Q12h to 4 mg/kg Q12h produces a 2.3-fold increase in exposure (Table 1).</p>
<a name="id_de5f8316-10a6-4d6b-8339-5588b1b5c850"></a><table width="325.000">
<caption><span>Table 1 Population Pharmacokinetic Parameters of Voriconazole in Subjects</span></caption>
<col align="left" width="20.0%">
<col align="center" width="20.0%">
<col align="center" width="20.0%">
<col align="center" width="20.0%">
<col align="center" width="20.0%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">200 mg Oral Q12h</td>
<td class="Rrule" align="left" valign="top">300 mg Oral Q12h</td>
<td class="Rrule" align="left" valign="top">3 mg/kg IV Q12h</td>
<td class="Botrule" align="left" valign="top">4 mg/kg IV Q12h</td>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Mean AUC<span class="Sub">τ</span> are predicted values from population pharmacokinetic analysis of data from 236 subjects</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Botrule" align="left" valign="top">AUC<span class="Sub">τ</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (µg∙h/mL)<br>(CV%)</td>
<td class="Botrule" align="left" valign="top">19.86<br>(94%)</td>
<td class="Botrule" align="left" valign="top">50.32<br>(74%)</td>
<td class="Botrule" align="left" valign="top">21.81<br>(100%)</td>
<td class="Botrule" align="left" valign="top">50.40<br>(83%)</td>
</tr></tbody>
</table>
<p>During oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> (mainly patients with malignant neoplasms of lymphatic or hematopoietic tissue), the observed pharmacokinetic characteristics were similar to those observed in healthy subjects (Table 2).</p>
<a name="id_a20978b1-6ddd-416f-9b50-434aab45a3d9"></a><table width="323.000">
<caption><span>Table 2 Pharmacokinetic Parameters of Voriconazole in Patients at Risk for <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">Aspergillosis</span></span></caption>
<col align="left" width="26.6%">
<col align="center" width="33.4%">
<col align="center" width="39.9%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">200 mg Oral Q12h<br>(n=9)</td>
<td class="Botrule" align="left" valign="top">300 mg Oral Q12h<br>(n=9)</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Geometric mean values on Day 14 of multiple dosing in 2 cohorts of patients</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">AUC<span class="Sub">τ</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> (µg∙h/mL )<br>(CV%)</td>
<td class="Botrule" align="left" valign="top">20.31<br>(69%)</td>
<td class="Botrule" align="left" valign="top">36.51<br>(45%)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">C<span class="Sub">max</span><a href="#footnote-2" class="Sup">*</a> (µg/mL)<br> (CV%) </td>
<td class="Botrule" align="left" valign="top">3.00<br>(51%)</td>
<td class="Botrule" align="left" valign="top">4.66<br>(35%)</td>
</tr>
</tbody>
</table>
<p>Sparse plasma sampling for pharmacokinetics was conducted in the therapeutic studies in patients aged 12–18 years. In 11 adolescent patients who received a mean voriconazole maintenance dose of 4 mg/kg IV, the median of the calculated mean plasma concentrations was 1.60 µg/mL (inter-quartile range 0.28 to 2.73 µg/mL). In 17 adolescent patients for whom mean plasma concentrations were calculated following a mean oral maintenance dose of 200 mg Q12h, the median of the calculated mean plasma concentrations was 1.16 µg/mL (inter-quartile range 0.85 to 2.14 µg/mL).</p>
<p>When the recommended intravenous or oral loading dose regimens are administered to healthy subjects, peak plasma concentrations close to steady state are achieved within the first 24 hours of dosing. Without the loading dose, accumulation occurs during twice-daily multiple dosing with steady-state peak plasma voriconazole concentrations being achieved by day 6 in the majority of subjects (Table 3).</p>
<a name="id_88a4281a-c779-4f09-ae78-5fe02fdd2b63"></a><table width="430.000">
<caption><span>Table 3 Pharmacokinetic Parameters of Voriconazole from Loading Dose and Maintenance Dose Regimens (Individual Studies in Subjects)</span></caption>
<col align="left" width="25.1%">
<col align="center" width="20.0%">
<col align="center" width="17.4%">
<col align="center" width="20.0%">
<col align="center" width="17.4%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">400 mg Q12h on Day 1,<br>200 mg Q12h on Days 2 to 10<br>(n=17)</td>
<td class="Botrule" align="left" colspan="2" valign="top">6 mg/kg IV<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> Q12h on Day 1,<br>3 mg/kg IV Q12h on Days 2 to 10<br>(n=9)</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">Day 1, 1<span class="Sup">st</span> dose</td>
<td class="Rrule" align="left" valign="top">Day 10</td>
<td class="Rrule" align="left" valign="top">Day 1, 1<span class="Sup">st</span> dose</td>
<td class="Botrule" align="left" valign="top">Day 10</td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>IV infusion over 60 minutes</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>AUC<span class="Sub">τ</span> values are calculated over dosing interval of 12 hours<br>Pharmacokinetic parameters for loading and maintenance doses summarized for same cohort of subjects</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">AUC<span class="Sub">τ</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a> (µg∙h/mL)<br>(CV%)</td>
<td class="Botrule" align="left" valign="top">9.31<br>(38%)</td>
<td class="Botrule" align="left" valign="top">11.13<br>(103%)</td>
<td class="Botrule" align="left" valign="top">13.22<br>(22%)</td>
<td class="Botrule" align="left" valign="top">13.25<br>(58%)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">C<span class="Sub">max</span> (µg/mL) <br>(CV%)</td>
<td class="Botrule" align="left" valign="top">2.30<br>(19%)</td>
<td class="Botrule" align="left" valign="top">2.08<br>(62%)</td>
<td class="Botrule" align="left" valign="top">4.70<br>(22%)</td>
<td class="Botrule" align="left" valign="top">3.06<br>(31%)</td>
</tr>
</tbody>
</table>
<p>Steady state trough plasma concentrations with voriconazole are achieved after approximately 5 days of oral or intravenous dosing without a loading dose regimen. However, when an intravenous loading dose regimen is used, steady state trough plasma concentrations are achieved within 1 day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1a87ed9-f5ec-46b5-b5e2-3f2da3e58239"></a><a name="section-2.2"></a><p></p>
<h2>Absorption</h2>
<p class="First">The pharmacokinetic properties of voriconazole are similar following administration by the intravenous and oral routes. Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%). Bioequivalence was established between the 200 mg tablet and the 40 mg/mL oral suspension when administered as a 400 mg Q12h loading dose followed by a 200 mg Q12h maintenance dose.</p>
<p>Maximum plasma concentrations (C<span class="Sub">max</span>) are achieved 1–2 hours after dosing. When multiple doses of voriconazole are administered with high-fat meals, the mean C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> are reduced by 34% and 24%, respectively when administered as a tablet and by 58% and 37% respectively when administered as the oral suspension (see <a href="#i4i_dosage_admin_id_40f5361c-a556-46cc-8ae1-92f7b209c2be">DOSAGE AND ADMINISTRATION</a>).</p>
<p>In healthy subjects, the absorption of voriconazole is not affected by coadministration of oral ranitidine, cimetidine, or omeprazole, drugs that are known to increase gastric pH.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20be22e7-a03d-4768-a13a-a722bcb494ba"></a><a name="section-2.3"></a><p></p>
<h2>Distribution</h2>
<p class="First">The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9–15 µg/mL). Varying degrees of hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> do not affect the protein binding of voriconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_761fabc9-d9ab-4caf-a967-412fecc2e3fa"></a><a name="section-2.4"></a><p></p>
<h2>Metabolism</h2>
<p class="First"><span class="Italics">In vitro</span> studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>).</p>
<p><span class="Italics">In vivo</span> studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15–20% of Asian populations may be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor metabolizers is 3–5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AUC<span class="Sub">τ</span>) than their homozygous extensive metabolizer counterparts. Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts.</p>
<p>The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. Since this metabolite has minimal antifungal activity, it does not contribute to the overall efficacy of voriconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_179dcc0f-e1e0-4f56-a73d-2215e0155a7d"></a><a name="section-2.5"></a><p></p>
<h2>Excretion</h2>
<p class="First">Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine. After administration of a single radiolabelled dose of either oral or IV voriconazole, preceded by multiple oral or IV dosing, approximately 80% to 83% of the radioactivity is recovered in the urine. The majority (&gt;94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.</p>
<p>As a result of non-linear pharmacokinetics, the terminal half-life of voriconazole is dose dependent and therefore not useful in predicting the accumulation or elimination of voriconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c2fd5d3c-a25a-4a24-a558-b1f185682e94"></a><a name="section-2.6"></a><p></p>
<h2>Pharmacokinetic-Pharmacodynamic Relationships</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_315b5265-d3fa-41de-b5a7-eb3a0f83aa47"></a><a name="section-2.6.1"></a><p></p>
<h3>Clinical Efficacy and Safety</h3>
<p class="First">In 10 clinical trials, the median values for the average and maximum voriconazole plasma concentrations in individual patients across these studies (N=1121) was 2.51 µg/mL (inter-quartile range 1.21 to 4.44 µg/mL) and 3.79 µg/mL (inter-quartile range 2.06 to 6.31 µg/mL), respectively. A pharmacokinetic-pharmacodynamic analysis of patient data from 6 of these 10 clinical trials (N=280) could not detect a positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy. However, PK/PD analyses of the data from all 10 clinical trials identified positive associations between plasma voriconazole concentrations and rate of both liver function test abnormalities and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (see <a href="#i4i_adverse_effects_id_cfa6573a-2c40-4c6c-a657-dc98fae1736d">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3022d4d-4f55-4def-bbb5-de22bc7de92c"></a><a name="section-2.6.2"></a><p></p>
<h3>Electrocardiogram</h3>
<p class="First">A placebo-controlled, randomized, crossover study to evaluate the effect on the QT interval of healthy male and female subjects was conducted with three single oral doses of voriconazole and ketoconazole. Serial ECGs and plasma samples were obtained at specified intervals over a 24-hour post dose observation period. The placebo-adjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600 mg of voriconazole and after ketoconazole 800 mg were all &lt;10 msec. Females exhibited a greater increase in QTc than males, although all mean changes were &lt;10 msec. Age was not found to affect the magnitude of increase in QTc. No subject in any group had an increase in QTc of ≥60 msec from baseline. No subject experienced an interval exceeding the potentially clinically relevant threshold of 500 msec. However, the QT effect of voriconazole combined with drugs known to prolong the QT interval is unknown (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS-Drug Interactions</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8979888c-fa68-4cc0-acae-c6eb14ff086d"></a><a name="section-2.7"></a><p></p>
<h2>Pharmacokinetics in Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3ca536e-e4e6-4f39-909e-d37e029cfcc2"></a><a name="section-2.7.1"></a><p></p>
<h3>Gender</h3>
<p class="First">In a multiple oral dose study, the mean C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> for healthy young females were 83% and 113% higher, respectively, than in healthy young males (18–45 years), after tablet dosing. In the same study, no significant differences in the mean C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> were observed between healthy elderly males and healthy elderly females (≥65 years). In a similar study, after dosing with the oral suspension, the mean AUC for healthy young females was 45% higher than in healthy young males whereas the mean C<span class="Sub">max</span> was comparable between genders. The steady state trough voriconazole concentrations (C<span class="Sub">min</span>) seen in females were 100% and 91% higher than in males receiving the tablet and the oral suspension, respectively.</p>
<p>In the clinical program, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female subjects were similar. Therefore, no dosage adjustment based on gender is necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4efe4f80-03a6-4c52-9188-02bbbbef6838"></a><a name="section-2.7.2"></a><p></p>
<h3>Geriatric</h3>
<p class="First">In an oral multiple dose study the mean C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> in healthy elderly males (≥ 65 years) were 61% and 86% higher, respectively, than in young males (18–45 years). No significant differences in the mean C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> were observed between healthy elderly females ( ≥ 65 years) and healthy young females (18–45 years).</p>
<p>In the clinical program, no dosage adjustment was made on the basis of age. An analysis of pharmacokinetic data obtained from 552 patients from 10 voriconazole clinical trials showed that the median voriconazole plasma concentrations in the elderly patients (&gt;65 years) were approximately 80% to 90% higher than those in the younger patients (≤65 years) after either IV or oral administration. However, the safety profile of voriconazole in young and elderly subjects was similar and, therefore, no dosage adjustment is necessary for the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3707b778-dea0-47ec-938c-93734b18721a"></a><a name="section-2.7.3"></a><p></p>
<h3>Pediatric</h3>
<p class="First">A population pharmacokinetic analysis was conducted on pooled data from 35 immunocompromised pediatric patients aged 2 to &lt;12 years old who were included in two pharmacokinetic studies of intravenous voriconazole (single dose and multiple dose). Twenty-four of these patients received multiple intravenous maintenance doses of 3 mg/kg and 4 mg/kg. A comparison of the pediatric and adult population pharmacokinetic data revealed that the predicted average steady state plasma concentrations were similar at the maintenance dose of 4 mg/kg every 12 hours in children and 3 mg/kg every 12 hours in adults (medians of 1.19 µg/mL and 1.16 µg/mL in children and adults, respectively) (see <a href="#i4i_pediatric_use_id_3a3cc1af-d3cf-430c-896a-96468b2b25ad">PRECAUTIONS, Pediatric Use</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dadae99c-c051-41ea-b6b7-07efdaceeec6"></a><a name="section-2.7.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h3>
<p class="First">After a single oral dose (200 mg) of voriconazole in 8 patients with mild (Child-Pugh Class A) and 4 patients with moderate (Child-Pugh Class B) <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, the mean systemic exposure (AUC) was 3.2-fold higher than in age and weight matched controls with normal hepatic function. There was no difference in mean peak plasma concentrations (C<span class="Sub">max</span>) between the groups. When only the patients with mild (Child-Pugh Class A) <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> were compared to controls, there was still a 2.3-fold increase in the mean AUC in the group with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> compared to controls.</p>
<p>In an oral multiple dose study, AUC<span class="Sub">τ</span> was similar in 6 subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B) given a lower maintenance dose of 100 mg twice daily compared to 6 subjects with normal hepatic function given the standard 200 mg twice daily maintenance dose. The mean peak plasma concentrations (C<span class="Sub">max</span>) were 20% lower in the hepatically impaired group.</p>
<p>It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child-Pugh Class A and B) receiving voriconazole. No pharmacokinetic data are available for patients with severe <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child-Pugh Class C) (see <a href="#i4i_dosage_admin_id_40f5361c-a556-46cc-8ae1-92f7b209c2be">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a835b637-c69a-4baa-88fa-2a6f50a5fb8e"></a><a name="section-2.7.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First">In a single oral dose (200 mg) study in 24 subjects with normal renal function and mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, systemic exposure (AUC) and peak plasma concentration (C<span class="Sub">max</span>) of voriconazole were not significantly affected by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Therefore, no adjustment is necessary for <span class="Underline">oral</span> dosing in patients with mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>In a multiple dose study of IV voriconazole (6 mg/kg IV loading dose × 2, then 3 mg/kg IV × 5.5 days) in 7 patients with moderate renal dysfunction (creatinine clearance 30–50 mL/min), the systemic exposure (AUC) and peak plasma concentrations (C<span class="Sub">max</span>) were not significantly different from those in 6 subjects with normal renal function.</p>
<p>However, in patients with moderate renal dysfunction (creatinine clearance 30–50 mL/min), accumulation of the intravenous vehicle, SBECD, occurs. The mean systemic exposure (AUC) and peak plasma concentrations (C<span class="Sub">max</span>) of SBECD were increased 4-fold and almost 50%, respectively, in the moderately impaired group compared to the normal control group.</p>
<p>Intravenous voriconazole should be avoided in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;50 mL/min), unless an assessment of the benefit/risk to the patient justifies the use of intravenous voriconazole (see <a href="#i4i_section_id_a197dd6f-9575-4548-83bc-b9d0459bbeb3">DOSAGE AND ADMINISTRATION - Dosage Adjustment</a>).</p>
<p>A pharmacokinetic study in subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> undergoing hemodialysis showed that voriconazole is dialyzed with clearance of 121 mL/min. The intravenous vehicle, SBECD, is hemodialyzed with clearance of 55 mL/min. A 4-hour hemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950"></a><a name="section-2.8"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_675cd30e-769f-4636-9a36-0675322126ac"></a><a name="section-2.8.1"></a><p></p>
<h3>Effects of Other Drugs on Voriconazole</h3>
<p class="First">Voriconazole is metabolized by the human hepatic cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. Results of <span class="Italics">in vitro</span> metabolism studies indicate that the affinity of voriconazole is highest for CYP2C19, followed by CYP2C9, and is appreciably lower for CYP3A4. Inhibitors or inducers of these three enzymes may increase or decrease voriconazole systemic exposure (plasma concentrations), respectively.</p>
<p><span class="Bold"><span class="Italics">The systemic exposure to voriconazole is significantly reduced or is expected to be reduced by the concomitant administration of the following agents and their use is contraindicated:</span></span></p>
<p><span class="Bold"><span class="Italics">Rifampin</span> (potent CYP450 inducer):</span> Rifampin (600 mg once daily) decreased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of voriconazole (200 mg Q12h × 7 days) by an average of 93% and 96%, respectively, in healthy subjects. Doubling the dose of voriconazole to 400 mg Q12h does not restore adequate exposure to voriconazole during coadministration with rifampin. <span class="Bold">Coadministration of voriconazole and rifampin is contraindicated</span> (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Ritonavir</span> (potent CYP450 inducer; CYP3A4 inhibitor and substrate):</span> The effect of the coadministration of voriconazole and ritonavir (400 mg and 100 mg) was investigated in two separate studies. High-dose ritonavir (400 mg Q12h for 9 days) decreased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) by an average of 66% and 82%, respectively, in healthy subjects. Low-dose ritonavir (100 mg Q12h for 9 days) decreased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) by an average of 24% and 39%, respectively<span class="Bold">,</span> in healthy subjects. Although repeat oral administration of voriconazole did not have a significant effect on steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of high-dose ritonavir in healthy subjects, steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of low-dose ritonavir decreased slightly by 24% and 14% respectively, when administered concomitantly with oral voriconazole in healthy subjects. <span class="Bold">Coadministration of voriconazole and high-dose ritonavir (400 mg Q12h) is contraindicated. Coadministration of voriconazole and low-dose ritonavir (100 mg Q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</span> (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">St. John's Wort</span> (CYP450 inducer; P-gp inducer):</span> In an independent published study in healthy volunteers who were given multiple oral doses of St. John's Wort (300 mg LI 160 extract three times daily for 15 days) followed by a single 400 mg oral dose of voriconazole, a 59% decrease in mean voriconazole AUC<span class="Sub">0–∞</span> was observed. In contrast, coadministration of single oral doses of St. John's Wort and voriconazole had no appreciable effect on voriconazole AUC<span class="Sub">0–∞</span>. Because long-term use of St. John's Wort could lead to reduced voriconazole exposure, <span class="Bold">concomitant use of voriconazole with St. John's Wort is contraindicated</span> (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>).</p>
<p><span class="Bold"><span class="Italics">Carbamazepine and long-acting barbiturates</span> (potent CYP450 inducers):</span> Although not studied <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span>, carbamazepine and long-acting barbiturates (e.g., phenobarbital, mephobarbital) are likely to significantly decrease plasma voriconazole concentrations. <span class="Bold">Coadministration of voriconazole with carbamazepine or long-acting barbiturates is contraindicated</span> (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Minor or no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> that do not require dosage adjustment:</span></span></p>
<p><span class="Bold"><span class="Italics">Cimetidine</span> (non-specific CYP450 inhibitor and increases gastric pH):</span> Cimetidine (400 mg Q12h × 8 days) increased voriconazole steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> by an average of 18% (90% CI: 6%, 32%) and 23% (90% CI: 13%, 33%), respectively, following oral doses of 200 mg Q12h × 7 days to healthy subjects.</p>
<p><span class="Bold"><span class="Italics">Ranitidine</span> (increases gastric pH):</span> Ranitidine (150 mg Q12h) had no significant effect on voriconazole C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> following oral doses of 200 mg Q12h × 7 days to healthy subjects.</p>
<p><span class="Bold"><span class="Italics">Macrolide antibiotics</span>:</span> Coadministration of <span class="Bold">erythromycin</span> (CYP3A4 inhibitor;1g Q12h for 7 days) or <span class="Bold">azithromycin</span> (500 mg qd for 3 days) with voriconazole 200 mg Q12h for 14 days had no significant effect on voriconazole steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> in healthy subjects. The effects of voriconazole on the pharmacokinetics of either erythromycin or azithromycin are not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02cf58ab-a26a-48a2-9953-b8ccf8cdb393"></a><a name="section-2.8.2"></a><p></p>
<h3>Effects of Voriconazole on Other Drugs</h3>
<p class="First"><span class="Italics">In vitro</span> studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. <span class="Italics">In vitro</span> studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.</p>
<p><span class="Bold"><span class="Italics">The systemic exposure of the following drugs is significantly increased or is expected to be significantly increased by coadministration of voriconazole and their use is contraindicated:</span></span></p>
<p><span class="Bold"><span class="Italics">Sirolimus</span> (CYP3A4 substrate):</span> Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the C<span class="Sub">max</span> and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects. <span class="Bold">Coadministration of voriconazole and sirolimus is contraindicated</span> (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Terfenadine, astemizole, cisapride, pimozide and quinidine</span> (CYP3A4 substrates):</span> Although not studied <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span>, concomitant administration of voriconazole with terfenadine, astemizole, cisapride, pimozide or quinidine may result in inhibition of the metabolism of these drugs. Increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span>. <span class="Bold">Coadministration of voriconazole and terfenadine, astemizole, cisapride, pimozide and quinidine is contraindicated</span> (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Ergot alkaloids</span>:</span> Although not studied <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span>, voriconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine) and lead to <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>. <span class="Bold">Coadministration of voriconazole with ergot alkaloids is contraindicated</span> (see <a href="#i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee">CONTRAINDICATIONS</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Coadministration of voriconazole with the following agents results in increased exposure or is expected to result in increased exposure to these drugs. Therefore, careful monitoring and/or dosage adjustment of these drugs is needed:</span></span></p>
<p><span class="Italics"><span class="Bold">Alfentanil (CYP3A4 substrate)</span>:</span> Coadministration of multiple doses of oral voriconazole (400 mg q12h on day 1, 200 mg q12h on day 2) with a single 20 mcg/kg intravenous dose of alfentanil with concomitant naloxone resulted in a 6-fold increase in mean alfentanil AUC<span class="Sub">0–∞</span> and a 4-fold prolongation of mean alfentanil elimination half-life, compared to when alfentanil was given alone. An increase in the incidence of delayed and persistent alfentanil-associated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> during co-administration of voriconazole and alfentanil was also observed. Reduction in the dose of alfentanil or other opiates that are also metabolized by CYP3A4 (e.g., sufentanil), and extended close monitoring of patients for respiratory and other opiate-associated adverse events, may be necessary when any of these opiates is coadministered with voriconazole. (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS – Drug Interactions</a>). </p>
<p><span class="Bold"><span class="Italics">Cyclosporine</span> (CYP3A4 substrate):</span> In stable renal transplant recipients receiving chronic cyclosporine therapy, concomitant administration of oral voriconazole (200 mg Q12h for 8 days) increased cyclosporine C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> an average of 1.1 times (90% CI: 0.9, 1.41) and 1.7 times (90% CI: 1.5, 2.0), respectively, as compared to when cyclosporine was administered without voriconazole. When initiating therapy with voriconazole in patients already receiving cyclosporine, it is recommended that the cyclosporine dose be reduced to one-half of the original dose and followed with frequent monitoring of the cyclosporine blood levels. Increased cyclosporine levels have been associated with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. <span class="Underline">When voriconazole is discontinued, cyclosporine levels should be frequently monitored and the dose increased as necessary</span> (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Methadone (CYP3A4, CYP2C19, CYP2C9 substrate): Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of pharmacologically active R-methadone by 31% (90% CI: 22%, 40%) and 47% (90% CI: 38%, 57%), respectively, in subjects receiving a methadone maintenance dose (30–100 mg QD). The C<span class="Sub">max</span> and AUC of (S)-methadone increased by 65% (90% CI: 53%, 79%) and 103% (90% CI: 85%, 124%), respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Tacrolimus</span> (CYP3A4 substrate):</span> Repeat oral dose administration of voriconazole (400 mg Q12h × 1 day, then 200 mg Q12h × 6 days) increased tacrolimus (0.1 mg/kg single dose) C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> in healthy subjects by an average of 2-fold (90% CI: 1.9, 2.5) and 3-fold (90% CI: 2.7, 3.8), respectively. When initiating therapy with voriconazole in patients already receiving tacrolimus, it is recommended that the tacrolimus dose be reduced to one-third of the original dose and followed with frequent monitoring of the tacrolimus blood levels. Increased tacrolimus levels have been associated with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. <span class="Underline">When voriconazole is discontinued, tacrolimus levels should be carefully monitored and the dose increased as necessary </span>(see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Warfarin</span> (CYP2C9 substrate):</span> Coadministration of voriconazole (300 mg Q12h × 12 days) with warfarin (30 mg single dose) significantly increased maximum <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time by approximately 2 times that of placebo in healthy subjects. Close monitoring of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or other suitable anticoagulation tests is recommended if warfarin and voriconazole are coadministered and the warfarin dose adjusted accordingly (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Oral Coumarin Anticoagulants </span></span><span class="Bold">(CYP2C9, CYP3A4 substrates):</span> Although not studied <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span>, voriconazole may increase the plasma concentrations of coumarin anticoagulants and therefore may cause an increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. If patients receiving coumarin preparations are treated simultaneously with voriconazole, the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or other suitable anti-coagulation tests should be monitored at close intervals and the dosage of anticoagulants adjusted accordingly (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Statins</span> (CYP3A4 substrates):</span> Although not studied clinically, voriconazole has been shown to inhibit lovastatin metabolism <span class="Italics">in vitro</span> (human liver microsomes). Therefore, voriconazole is likely to increase the plasma concentrations of statins that are metabolized by CYP3A4. It is recommended that dose adjustment of the statin be considered during coadministration. Increased statin concentrations in plasma have been associated with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Benzodiazepines</span> (CYP3A4 substrates):</span> Although not studied clinically, voriconazole has been shown to inhibit midazolam metabolism <span class="Italics">in vitro</span> (human liver microsomes). Therefore, voriconazole is likely to increase the plasma concentrations of benzodiazepines that are metabolized by CYP3A4 (e.g., midazolam, triazolam, and alprazolam) and lead to a prolonged sedative effect. It is recommended that dose adjustment of the benzodiazepine be considered during coadministration (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Calcium Channel Blockers</span> (CYP3A4 substrates):</span> Although not studied clinically, voriconazole has been shown to inhibit felodipine metabolism <span class="Italics">in vitro</span> (human liver microsomes). Therefore, voriconazole may increase the plasma concentrations of calcium channel blockers that are metabolized by CYP3A4. Frequent monitoring for adverse events and toxicity related to calcium channel blockers is recommended during coadministration. Dose adjustment of the calcium channel blocker may be needed (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Sulfonylureas <span class="Bold">(CYP2C9 substrates):</span> Although not studied <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span>, voriconazole may increase plasma concentrations of sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) and therefore cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Frequent monitoring of blood glucose and appropriate adjustment (i.e., reduction) of the sulfonylurea dosage is recommended during coadministration (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Vinca Alkaloids </span></span><span class="Bold">(CYP3A4 substrates):</span> Although not studied <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span>, voriconazole may increase the plasma concentrations of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>. Therefore, it is recommended that dose adjustment of the vinca alkaloid be considered.</p>
<p><span class="Bold"><span class="Italics">No significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when voriconazole was coadministered with the following agents. Therefore, no dosage adjustment for these agents is recommended:</span></span></p>
<p><span class="Bold"><span class="Italics">Prednisolone</span> (CYP3A4 substrate):</span> Voriconazole (200 mg Q12h × 30 days) increased C<span class="Sub">max</span> and AUC of prednisolone (60 mg single dose) by an average of 11% and 34%, respectively, in healthy subjects.</p>
<p><span class="Bold"><span class="Italics">Digoxin</span> (P-glycoprotein mediated transport):</span> Voriconazole (200 mg Q12h × 12 days) had no significant effect on steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of digoxin (0.25 mg once daily for 10 days) in healthy subjects.</p>
<p><span class="Bold"><span class="Italics">Mycophenolic acid</span> (UDP-glucuronyl transferase substrate):</span> Voriconazole (200 mg Q12h × 5 days) had no significant effect on the C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of mycophenolic acid and its major metabolite, mycophenolic acid glucuronide after administration of a 1 g single oral dose of mycophenolate mofetil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f18a6c6-572a-4512-a1ed-73c236c9e5d0"></a><a name="section-2.8.3"></a><p></p>
<h3>Two-Way Interactions</h3>
<p class="First"><span class="Bold"><span class="Italics">Concomitant use of the following agents with voriconazole is contraindicated:</span></span></p>
<p><span class="Bold"><span class="Italics">Rifabutin</span> (potent CYP450 inducer):</span> Rifabutin (300 mg once daily) decreased the C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of voriconazole at 200 mg twice daily by an average of 67% (90% CI: 58%, 73%) and 79% (90% CI: 71%, 84%), respectively, in healthy subjects. During coadministration with rifabutin (300 mg once daily), the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of voriconazole following an increased dose of 400 mg twice daily were on average approximately 2 times higher, compared with voriconazole alone at 200 mg twice daily. Coadministration of voriconazole at 400 mg twice daily with rifabutin 300 mg twice daily increased the C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of rifabutin by an average of 3-times (90% CI: 2.2, 4.0) and 4 times (90% CI: 3.5, 5.4), respectively, compared to rifabutin given alone. <span class="Bold">Coadministration of voriconazole and rifabutin is contraindicated.</span></p>
<p><span class="Bold"><span class="Italics">Significant drug interactions that may require dosage adjustment, frequent monitoring of drug levels and/or frequent monitoring of drug-related adverse events/toxicity:</span></span></p>
<p><span class="Bold"><span class="Italics">Efavirenz</span>, a non-nucleoside reverse transcriptase inhibitor (CYP450 inducer; CYP3A4 inhibitor and substrate):</span> Standard doses of voriconazole and standard doses of efavirenz must not be coadministered (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS – Drug Interactions</a>). Steady state efavirenz (400 mg PO QD) decreased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of voriconazole (400 mg PO Q12h for 1 day, then 200 mg PO Q12h for 8 days) by an average of 61% and 77%, respectively, in healthy male subjects. Voriconazole at steady state (400 mg PO Q12h for 1 day, then 200 mg Q12h for 8 days) increased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of efavirenz (400 mg PO QD for 9 days) by an average of 38% and 44%, respectively, in healthy subjects.</p>
<p>The pharmacokinetics of adjusted doses of voriconazole and efavirenz were studied in healthy male subjects following administration of voriconazole (400 mg PO Q12h on Days 2 to 7) with efavirenz (300 mg PO Q24h on Days 1–7), relative to steady-state administration of voriconazole (400 mg for 1 day, then 200 mg PO Q12h for 2 days) or efavirenz (600 mg Q24h for 9 days). Coadministration of voriconazole 400 mg Q 12h with efavirenz 300 mg Q24h, decreased voriconazole AUCτ by 7% (90% CI: -23%, 13%) and increased Cmax by 23% (90% CI: -1%, 53%); efavirenz AUCτ was increased by 17% (90% CI: 6%, 29%) and Cmax was equivalent.</p>
<p>Voriconazole may be coadministered with efavirenz if the voriconazole maintenance dose is increased to 400 mg Q12h and the efavirenz dose is decreased to 300 mg Q24h. When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored.</p>
<p><span class="Bold"><span class="Italics">Phenytoin</span> (CYP2C9 substrate and potent CYP450 inducer):</span> Repeat dose administration of phenytoin (300 mg once daily) decreased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of orally administered voriconazole (200 mg Q12h × 14 days) by an average of 50% and 70%, respectively, in healthy subjects. Administration of a higher voriconazole dose (400 mg Q12h × 7 days) with phenytoin (300 mg once daily) resulted in comparable steady state voriconazole C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> estimates as compared to when voriconazole was given at 200 mg Q12h without phenytoin.</p>
<p>Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased from 4 mg/kg to 5 mg/kg intravenously every 12 hours or from 200 mg to 400 mg orally, every 12 hours (100 mg to 200 mg orally, every 12 hours in patients less than 40 kg) (see <a href="#i4i_dosage_admin_id_40f5361c-a556-46cc-8ae1-92f7b209c2be">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Repeat dose administration of voriconazole (400 mg Q12h × 10 days) increased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of phenytoin (300 mg once daily) by an average of 70% and 80%, respectively, in healthy subjects. The increase in phenytoin C<span class="Sub">max</span> and AUC when coadministered with voriconazole may be expected to be as high as 2 times the C<span class="Sub">max</span> and AUC estimates when phenytoin is given without voriconazole. Therefore, frequent monitoring of plasma phenytoin concentrations and phenytoin-related adverse effects is recommended when phenytoin is coadministered with voriconazole (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Omeprazole</span> (CYP2C19 inhibitor; CYP2C19 and CYP3A4 substrate)</span>: Coadministration of omeprazole (40 mg once daily × 10 days) with oral voriconazole (400 mg Q12h × 1 day, then 200 mg Q12h × 9 days) increased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of voriconazole by an average of 15% (90% CI: 5%, 25%) and 40% (90% CI: 29%, 55%), respectively, in healthy subjects. No dosage adjustment of voriconazole is recommended.</p>
<p>Coadministration of voriconazole (400 mg Q12h × 1 day, then 200 mg × 6 days) with omeprazole (40 mg once daily × 7 days) to healthy subjects significantly increased the steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of omeprazole an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4), respectively, as compared to when omeprazole is given without voriconazole. When initiating voriconazole in patients already receiving omeprazole doses of 40 mg or greater, it is recommended that the omeprazole dose be reduced by one-half (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>The metabolism of other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of these drugs.</p>
<p><span class="Bold"><span class="Italics">Oral Contraceptives</span></span> <span class="Bold">(CYP3A4 substrate; CYP2C19 inhibitor)</span>: Coadministration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 3 days) and oral contraceptive (Ortho-Novum1/35® consisting of 35 mcg ethinyl estradiol and 1 mg norethindrone, Q24h) to healthy female subjects at steady state increased the C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of ethinyl estradiol by an average of 36% (90% CI: 28%, 45%) and 61% (90% CI: 50%, 72%), respectively, and that of norethindrone by 15% (90% CI: 3%, 28%) and 53% (90% CI: 44%, 63%), respectively in healthy subjects. Voriconazole C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> increased by an average of 14% (90% CI: 3%, 27%) and 46% (90% CI: 32%, 61%), respectively. Monitoring for adverse events related to oral contraceptives, in addition to those for voriconazole, is recommended during coadministration (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">No significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was seen and no dosage adjustment of these drugs is recommended:</span></span></p>
<p><span class="Bold"><span class="Italics">Indinavir</span> (CYP3A4 inhibitor and substrate):</span> Repeat dose administration of indinavir (800 mg TID for 10 days) had no significant effect on voriconazole C<span class="Sub">max</span> and AUC following repeat dose administration (200 mg Q12h for 17 days) in healthy subjects.</p>
<p>Repeat dose administration of voriconazole (200 mg Q12h for 7 days) did not have a significant effect on steady state C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> of indinavir following repeat dose administration (800 mg TID for 7 days) in healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a23af3db-9d36-48fb-bd4b-109f4c7aac68"></a><a name="section-2.8.4"></a><p></p>
<h3>Other Two-Way Interactions Expected to be Significant Based on <span class="Italics">In Vitro</span> and <span class="Italics">In Vivo</span> Findings</h3>
<p class="First"><span class="Bold"><span class="Italics">Other HIV Protease Inhibitors</span> (CYP3A4 substrates and inhibitors): </span><span class="Italics">In vitro</span> studies (human liver microsomes) suggest that voriconazole may inhibit the metabolism of HIV protease inhibitors (e.g., saquinavir, amprenavir and nelfinavir). <span class="Italics">In vitro</span> studies (human liver microsomes) also show that the metabolism of voriconazole may be inhibited by HIV protease inhibitors (e.g., saquinavir and amprenavir). Patients should be frequently monitored for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span> during the coadministration of voriconazole and HIV protease inhibitors (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p><span class="Bold"><span class="Italics">Other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</span> (CYP3A4 substrates, inhibitors or CYP450 inducers)</span>: <span class="Italics">In vitro</span> studies (human liver microsomes) show that the metabolism of voriconazole may be inhibited by a NNRTI (e.g., delavirdine). The findings of a clinical voriconazole-efavirenz drug interaction study in healthy male subjects suggest that the metabolism of voriconazole may be induced by a NNRTI. This <span class="Italics">in vivo</span> study also showed that voriconazole may inhibit the metabolism of a NNRTI (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY – Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS – Drug Interactions</a>). Patients should be frequently monitored for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span> during the coadministration of voriconazole and other NNRTIs (e.g., nevirapine and delavirdine) (see <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>). Dose adjustments are required when voriconazole is co-administered with efavirenz (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_1586fc0c-3582-4f81-844f-e8789653956f"></a><a name="section-3"></a><p></p>
<h1>MICROBIOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a333b6a-8dcd-40e3-941c-6fd26837b00e"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8953cb6b-8262-43f6-b6e9-3c2c58cac7c3"></a><a name="section-3.2"></a><p></p>
<h2>Activity <span class="Italics">In Vitro</span>
</h2>
<p class="First">Voriconazole has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, <span class="Bold">both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></p>
<p><span class="Italics">Aspergillus fumigatus<br>Aspergillus flavus<br> Aspergillus niger<br> Aspergillus terreus<br> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans<br> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> glabrata</span> (In clinical studies, the voriconazole MIC<span class="Sub">90</span> was 4 µg/mL)<a name="footnote-reference-5" href="#footnote-5" class="Sup">1</a><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei<br> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis<br> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> tropicalis<br> Fusarium</span> spp. including <span class="Italics">Fusarium solani<br> Scedosporium apiospermum</span></p>
<p>The following data are available, <span class="Bold">but their clinical significance is unknown.</span></p>
<p>Voriconazole exhibits <span class="Italics">in vitro</span> minimal inhibitory concentrations (MICs) of 1 µg/mL or less against most (≥90%) isolates of the following microorganisms; however, the safety and effectiveness of voriconazole in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species have not been established in adequate and well-controlled clinical trials:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> lusitaniae<br><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> guilliermondii</span></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">1</a></dt>
<dd><p class="First">In clinical studies, voriconazole MIC<span class="Sub">90</span> for <span class="Italics">C. glabrata</span> baseline isolates was 4 µg/mL; 13/50 (26%) <span class="Italics">C. glabrata</span> baseline isolates were resistant (MIC ≥4 µg/mL) to voriconazole. However, based on 1054 isolates tested in surveillance studies the MIC<span class="Sub">90</span> was 1 µg/mL (see <a href="#id_dde47438-882f-4dd0-83f2-5f364b4dab75">Table 4</a>).</p></dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_45eec0cc-e7ce-4bb6-aa20-d0ad820a8e47"></a><a name="section-3.2.1"></a><p></p>
<h3>Susceptibility Testing Methods<span class="Sup">2,3</span>
</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d768cc56-6c8b-460d-89ed-16a1e4ef0352"></a><a name="section-3.2.1.1"></a><p></p>
<h4> Aspergillus species and other filamentous fungi</h4>
<p class="First">No interpretive criteria have been established for <span class="Italics">Aspergillus</span> species and other filamentous fungi.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed40d263-0323-4e31-b872-87d32e3334d3"></a><a name="section-3.2.1.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> species</h4>
<p class="First">The interpretive standards for voriconazole against <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species are applicable only to tests performed using Clinical Laboratory and Standards Institute (CLSI) microbroth dilution reference method M27 for MIC read at 48 hours or disk diffusion reference method M44 for zone diameter read at 24 hours.<span class="Sup">2,3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0840c6c-b511-4b71-b97d-6643209fe26b"></a><a name="section-3.2.1.3"></a><p></p>
<h4>Broth Microdilution Techniques</h4>
<p class="First">Quantitative methods are used to determine antifungal <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> spp. to antifungal agents. MICs should be determined using a standardized procedure at 48 hours.<span class="Sup">2</span> Standardized procedures are based on a microdilution method (broth) with standardized inoculum concentrations and standardized concentrations of voriconazole powder. The MIC values should be interpreted according to the criteria provided in Table 4.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2619b210-4b68-4972-84cf-8f0fc2c45bf9"></a><a name="section-3.2.1.4"></a><p></p>
<h4>Diffusion Techniques</h4>
<p class="First">Qualitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> spp. to an antifungal agent. One such standardized procedure requires the use of standardized inoculum concentrations.<span class="Sup">3</span> This procedure uses paper disks impregnated with 1 µg of voriconazole to test the susceptibility of yeasts to voriconazole at 24 hours. Disk diffusion interpretive criteria are also provided in Table 4.</p>
<a name="id_dde47438-882f-4dd0-83f2-5f364b4dab75"></a><table width="429.000">
<caption><span>Table 4: Susceptibility Interpretive Criteria for Voriconazole<span class="Sup">2,3</span></span></caption>
<col align="center" width="16.1%">
<col align="center" width="14.0%">
<col align="center" width="14.0%">
<col align="center" width="14.0%">
<col align="center" width="14.0%">
<col align="center" width="14.0%">
<col align="center" width="14.0%">
<thead>
<tr class="First Toprule">
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">Broth Microdilution at 48 hours<br>(MIC in µg/mL) </td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">Disk Diffusion at 24 hours<br>(Zone diameters in mm)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Susceptible (S)</td>
<td class="Rrule" align="left" valign="top">Intermediate (I)</td>
<td class="Rrule" align="left" valign="top">Resistant (R)</td>
<td class="Rrule" align="left" valign="top">Susceptible (S)</td>
<td class="Rrule" align="left" valign="top">Intermediate (I)</td>
<td class="Rrule" align="left" valign="top">Resistant (R)</td>
</tr>
</thead>
<tfoot><tr class="Last"><td class="Lrule Rrule" align="left" colspan="7" valign="top">
<span class="Bold">NOTE:</span> Shown are the breakpoints (µg/mL) for voriconazole against <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species. </td></tr></tfoot>
<tbody><tr class="First Last Toprule">
<td class="Lrule" align="left" valign="top">Voriconazole</td>
<td class="Toprule" align="left" valign="top">≤1.0</td>
<td class="Toprule" align="left" valign="top">2.0</td>
<td class="Toprule" align="left" valign="top">≥4.0</td>
<td class="Toprule" align="left" valign="top">≥17</td>
<td class="Toprule" align="left" valign="top">14–16</td>
<td class="Rrule" align="left" valign="top">≤13</td>
</tr></tbody>
</table>
<p>The susceptible category implies that isolates are inhibited by the usually achievable concentrations of antifungal agent tested when the recommended dosage is used for the site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The intermediate category implies that an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> due to the isolate may be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug is used. The resistant category implies that isolates are not inhibited by the usually achievable concentrations of the agent with normal dosage schedules and clinical efficacy of the agent against the isolate has not been reliably shown in treatment studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c64d5e3e-ecea-474b-af48-1241de530472"></a><a name="section-3.2.2"></a><p></p>
<h3>Quality Control </h3>
<p class="First">Standardized susceptibility test procedures require the use of quality control organisms to control the technical aspects of the test procedures. Standard voriconazole powder and 1 µg disks should provide the following range of values noted in Table 5.</p>
<p><span class="Bold">NOTE:</span> Quality control microorganisms are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within fungi; the specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for microbiological control are not clinically significant.</p>
<a name="id_de8a42ed-3cac-4011-91a9-85978d656ba8"></a><table width="430.000">
<caption><span>Table 5 Acceptable Quality Control Ranges for Voriconazole to be used in Validation of Susceptibility Test Results </span></caption>
<col align="center" width="34.0%">
<col align="center" width="33.0%">
<col align="center" width="33.0%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="middle">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></td>
<td class="Rrule" align="left" valign="top">Broth Microdilution (MIC in µg/mL) @ 48-hour</td>
<td class="Rrule" align="left" valign="top">Disk Diffusion (Zone diameter in mm) @ 24- hour</td>
</tr></thead>
<tfoot>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="3" valign="top">ATCC is a registered trademark of the American Type Culture Collection.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Quality control ranges have not been established for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>/antifungal agent combination due to their extensive interlaboratory variation during initial quality control studies.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule" align="left" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis</span><br>ATCC 22019</td>
<td class="Toprule" align="left" valign="top">0.03–0.25</td>
<td class="Rrule" align="left" valign="top">28–37</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei</span><br>ATCC 6258</td>
<td align="left" valign="top">0.12–1.0</td>
<td class="Rrule" align="left" valign="top">16–25</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span><br>ATCC 90028</td>
<td align="left" valign="top"><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></td>
<td class="Rrule" align="left" valign="top">31–42</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da15a966-32ac-4f15-a8de-4f02b8706cba"></a><a name="section-3.3"></a><p></p>
<h2>Activity <span class="Italics">In Vivo</span>
</h2>
<p class="First">Voriconazole was active in normal and/or immunocompromised guinea pigs with systemic and/or pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">A. fumigatus</span> (including an isolate with reduced susceptibility to itraconazole) or <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species <span class="Italics">[C.albicans</span> (including an isolate with reduced susceptibility to fluconazole), <span class="Italics">C. krusei and C. glabrata]</span> in which the endpoints were prolonged survival of infected animals and/or reduction of mycological burden from target organs. In one experiment, voriconazole exhibited activity against <span class="Italics">Scedosporium apiospermum</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in immune competent guinea pigs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4fa792d7-8c80-4b46-b783-c2c1ad3fe0b0"></a><a name="section-3.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First">Voriconazole <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> development has not been adequately studied <span class="Italics">in vitro</span> against <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Aspergillus, Scedosporium</span> and <span class="Italics">Fusarium</span> species. The frequency of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> development for the various fungi for which this drug is indicated is not known.</p>
<p>Fungal isolates exhibiting reduced susceptibility to fluconazole or itraconazole may also show reduced susceptibility to voriconazole, suggesting cross-resistance can occur among these azoles. The relevance of cross-resistance and clinical outcome has not been fully characterized. Clinical cases where azole cross-resistance is demonstrated may require alternative antifungal therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0d8a96bd-7996-4972-8b47-48c906d4c989"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">VFEND is indicated for use in the treatment of the following <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>:</p>
<p>Invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>. In clinical trials, the majority of isolates recovered were <span class="Italics">Aspergillus fumigatus</span>. There was a small number of cases of culture-proven disease due to species of <span class="Italics">Aspergillus</span> other than <span class="Italics">A. fumigatus</span> (see <a href="#i4i_clinical_studies_id_9d2cdbf1-461a-4079-811c-c3203b789776">CLINICAL STUDIES</a>, <a href="#i4i_microbiology_id_1586fc0c-3582-4f81-844f-e8789653956f">MICROBIOLOGY</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> in nonneutropenic patients and the following <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in skin and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in abdomen, kidney, bladder wall, and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> (see <a href="#i4i_clinical_studies_id_9d2cdbf1-461a-4079-811c-c3203b789776">CLINICAL STUDIES</a>, <a href="#i4i_microbiology_id_1586fc0c-3582-4f81-844f-e8789653956f">MICROBIOLOGY</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal candidiasis</span> (see <a href="#i4i_clinical_studies_id_9d2cdbf1-461a-4079-811c-c3203b789776">CLINICAL STUDIES</a>, <a href="#i4i_microbiology_id_1586fc0c-3582-4f81-844f-e8789653956f">MICROBIOLOGY</a>).</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> caused by <span class="Italics">Scedosporium apiospermum</span> (asexual form of <span class="Italics">Pseudallescheria boydii</span>) and <span class="Italics">Fusarium</span> spp. including <span class="Italics">Fusarium solani,</span> in patients intolerant of, or refractory to, other therapy (see <a href="#i4i_clinical_studies_id_9d2cdbf1-461a-4079-811c-c3203b789776">CLINICAL STUDIES</a>, <a href="#i4i_microbiology_id_1586fc0c-3582-4f81-844f-e8789653956f">MICROBIOLOGY</a>).</p>
<p>Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_9d2cdbf1-461a-4079-811c-c3203b789776"></a><a name="section-5"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Voriconazole, administered orally or parenterally, has been evaluated as primary or salvage therapy in 520 patients aged 12 years and older with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Aspergillus</span> spp., <span class="Italics">Fusarium</span> spp., and <span class="Italics">Scedosporium</span> spp.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7d56267-5c05-4813-8cf3-b0b90b8eb92a"></a><a name="section-5.1"></a><p></p>
<h2>Invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">Aspergillosis</span></h2>
<p class="First">Voriconazole was studied in patients for primary therapy of invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> (randomized, controlled study 307/602), for primary and salvage therapy of <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> (non-comparative study 304) and for treatment of patients with invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> who were refractory to, or intolerant of, other antifungal therapy (non-comparative study 309/604).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fcc38b5f-6abf-4414-af9d-9b3928af100e"></a><a name="section-5.2"></a><p></p>
<h2>Study 307/602</h2>
<p class="First">The efficacy of voriconazole compared to amphotericin B in the primary treatment of acute invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> was demonstrated in 277 patients treated for 12 weeks in Study 307/602. The majority of study patients had underlying hematologic malignancies, including bone marrow transplantation. The study also included patients with solid organ transplantation, <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, and AIDS. The patients were mainly treated for definite or probable invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> of the lungs. Other <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> included disseminated disease, CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infections</span>. Diagnosis of definite or probable invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> was made according to criteria modified from those established by the National Institute of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> and Infectious Diseases Mycoses Study Group/European Organisation for Research and Treatment of Cancer (NIAID MSG/EORTC).</p>
<p>Voriconazole was administered intravenously with a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours for a minimum of seven days. Therapy could then be switched to the oral formulation at a dose of 200 mg Q12h. Median duration of IV voriconazole therapy was 10 days (range 2–90 days). After IV voriconazole therapy, the median duration of PO voriconazole therapy was 76 days (range 2–232 days).</p>
<p>Patients in the comparator group received conventional amphotericin B as a slow infusion at a daily dose of 1.0–1.5 mg/kg/day. Median duration of IV amphotericin therapy was 12 days (range 1–85 days). Treatment was then continued with other licensed antifungal therapy (OLAT), including itraconazole and lipid amphotericin B formulations. Although initial therapy with conventional amphotericin B was to be continued for at least two weeks, actual duration of therapy was at the discretion of the investigator. Patients who discontinued initial randomized therapy due to toxicity or lack of efficacy were eligible to continue in the study with OLAT treatment.</p>
<p>A satisfactory global response at 12 weeks (complete or partial resolution of all attributable symptoms, signs, radiographic/bronchoscopic abnormalities present at baseline) was seen in 53% of voriconazole treated patients compared to 32% of amphotericin B treated patients (Table 6). A benefit of voriconazole compared to amphotericin B on patient survival at Day 84 was seen with a 71% survival rate on voriconazole compared to 58% on amphotericin B (Table 6).</p>
<p>Table 6 also summarizes the response (success) based on mycological confirmation and species.</p>
<a name="id_4fc1751a-e014-40a3-91cf-92f43fc496da"></a><table width="388.000">
<caption><span>Table 6 Overall Efficacy and Success by Species in the Primary Treatment of Acute Invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">Aspergillosis</span> Study 307/602 </span></caption>
<col align="left" width="27.8%">
<col align="center" width="22.2%">
<col align="center" width="22.2%">
<col align="center" width="27.8%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Voriconazole</td>
<td class="Botrule Rrule" align="left" valign="top">Ampho B <a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Botrule" align="left" valign="top">Stratified Difference (95% CI) <a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">n/N (%)</td>
<td class="Rrule" align="left" valign="top">n/N (%)</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Amphotericin B followed by other licensed antifungal therapy</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Difference and corresponding 95% confidence interval are stratified by protocol</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>Assessed by independent Data Review Committee (DRC)</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt>
<dd>Proportion of subjects alive</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">¶</a></dt>
<dd>Not all mycologically confirmed specimens were speciated</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">#</a></dt>
<dd>Some patients had more than one species isolated at baseline</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"><span class="Bold">Efficacy as Primary Therapy</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">  Satisfactory Global<br>  Response <a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Botrule" align="left" valign="top">76/144 (53)</td>
<td class="Botrule" align="left" valign="top">42/133 (32)</td>
<td class="Botrule" align="left" valign="top">21.8%<br>(10.5%, 33.0%)<br>p&lt;0.0001 </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">  Survival at Day 84 <a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a>
</td>
<td class="Botrule" align="left" valign="top">102/144 (71)</td>
<td class="Botrule" align="left" valign="top">77/133 (58)</td>
<td class="Botrule" align="left" valign="top">13.1%<br>(2.1%, 24.2%)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Success by Species</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" colspan="2" valign="top"><span class="Bold">Success n/N (%)</span></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">  Overall success</td>
<td class="Botrule" align="left" valign="top">76/144 (53)</td>
<td class="Botrule" align="left" valign="top">42/133 (32)</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    Mycologically<br>    confirmed <a name="footnote-reference-11" href="#footnote-11" class="Sup">¶</a>
</td>
<td class="Botrule" align="left" valign="top">37/84 (44)</td>
<td class="Botrule" align="left" valign="top"> 16/67 (24)</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">  Aspergillus spp.<a name="footnote-reference-12" href="#footnote-12" class="Sup">#</a>
</td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    A. fumigatus</td>
<td class="Botrule" align="left" valign="top"> 28/63 (44)</td>
<td class="Botrule" align="left" valign="top">12/47 (26)</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    A. flavus</td>
<td class="Botrule" align="left" valign="top">3/6</td>
<td class="Botrule" align="left" valign="top">4/9</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    A. terreus</td>
<td class="Botrule" align="left" valign="top">2/3</td>
<td class="Botrule" align="left" valign="top">0/3</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">    A. niger</td>
<td class="Botrule" align="left" valign="top">1/4</td>
<td class="Botrule" align="left" valign="top">0/9</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">    A. nidulans</td>
<td class="Botrule" align="left" valign="top">1/1</td>
<td class="Botrule" align="left" valign="top">0/0</td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6d94ef2-9735-405d-af7f-b8b0faf6eb5c"></a><a name="section-5.3"></a><p></p>
<h2>Study 304</h2>
<p class="First">The results of this comparative trial (Study 307/602) confirmed the results of an earlier trial in the primary and salvage treatment of patients with acute invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> (Study 304). In this earlier study, an overall success rate of 52% (26/50) was seen in patients treated with voriconazole for primary therapy. Success was seen in 17/29 (59%) with <span class="Italics">Aspergillus fumigatus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and 3/6 (50%) patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to non-<span class="Italics">fumigatus</span> species [<span class="Italics">A. flavus</span> (1/1); <span class="Italics">A. nidulans</span> (0/2); <span class="Italics">A. niger</span> (2/2); <span class="Italics">A. terreus</span> (0/1)]. Success in patients who received voriconazole as salvage therapy is presented in Table 7.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_632b8fe8-473d-4268-90db-a076b4e1c17f"></a><a name="section-5.4"></a><p></p>
<h2>Study 309/604</h2>
<p class="First">Additional data regarding response rates in patients who were refractory to, or intolerant of, other antifungal agents are also provided in Table 7. Overall mycological eradication for culture-documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">fumigatus</span> and non-<span class="Italics">fumigatus</span> species of <span class="Italics">Aspergillus</span> was 36/82 (44%) and 12/30 (40%), respectively, in voriconazole treated patients. Patients had various underlying diseases and species other than <span class="Italics">A. fumigatus</span> contributed to mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in some cases.</p>
<p>For patients who were infected with a single pathogen and were refractory to, or intolerant of, other antifungal agents, the satisfactory response rates for voriconazole in studies 304 and 309/604 are presented in Table 7.</p>
<a name="id_547aba04-b45a-4dc3-b5cc-8b1df7ebd1b5"></a><table width="216.000">
<caption><span>Table 7 Combined Response Data in Salvage Patients with Single Aspergillus Species (Studies 304 and 309/604)</span></caption>
<col align="left" width="50.0%">
<col align="left" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Success<br>n/N</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">
<br>A. fumigatus</td>
<td class="Botrule" align="left" valign="top">
<br>43/97 (44%)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">A. flavus</td>
<td class="Botrule" align="left" valign="top"> 5/12</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">A. nidulans</td>
<td class="Botrule" align="left" valign="top"> 1/3</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">A. niger</td>
<td class="Botrule" align="left" valign="top">4/5</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">A. terreus</td>
<td class="Botrule" align="left" valign="top"> 3/8</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">A. versicolor</td>
<td class="Botrule" align="left" valign="top"> 0/1</td>
</tr>
</tbody>
</table>
<p>Nineteen patients had more than one species of <span class="Italics">Aspergillus</span> isolated. Success was seen in 4/17 (24%) of these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e4176d7-591f-4627-9757-e7beb7d9b6d1"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> in nonneutropenic patients and other deep tissue <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></h2>
<p class="First">Voriconazole was compared to the regimen of amphotericin B followed by fluconazole in Study 608, an open label, comparative study in nonneutropenic patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> associated with clinical signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients were randomized in 2:1 ratio to receive either voriconazole (n=283) or the regimen of amphotericin B followed by fluconazole (n=139). Patients were treated with randomized study drug for a median of 15 days. Most of the <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> in patients evaluated for efficacy was caused by <span class="Italics">C. albicans</span> (46%), followed by <span class="Italics">C. tropicalis</span> (19%), <span class="Italics">C. parapsilosis</span> (17%), <span class="Italics">C. glabrata</span> (15%), and <span class="Italics">C. krusei</span> (1%).</p>
<p>An independent Data Review Committee (DRC), blinded to study treatment, reviewed the clinical and mycological data from this study, and generated one assessment of response for each patient. A successful response required all of the following: resolution or improvement in all clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, blood cultures negative for <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>, infected deep tissue sites negative for <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> or resolution of all local signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and no systemic antifungal therapy other than study drug. The primary analysis, which counted DRC-assessed successes at the fixed time point (12 weeks after End of Therapy [EOT]), demonstrated that voriconazole was comparable to the regimen of amphotericin B followed by fluconazole (response rates of 41% and 41%, respectively) in the treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>. Patients who did not have a 12-week assessment for any reason were considered a treatment failure.</p>
<p>The overall clinical and mycological success rates by <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species in Study 150-608 are presented in Table 8.</p>
<a name="id_de89cf9c-9690-428e-9588-cb0bdf56e395"></a><table width="258.000">
<caption><span>Table 8 Overall Success Rates Sustained From EOT To The Fixed 12-Week Follow-Up Time Point By Baseline Pathogen<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a></span></caption>
<col align="left" width="33.3%">
<col align="center" width="33.3%">
<col align="center" width="33.3%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" rowspan="2" valign="top">Baseline Pathogen </td>
<td class="Botrule" align="left" colspan="2" valign="top">Clinical and Mycological Success (%)</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top">Voriconazole</td>
<td class="Botrule" align="left" valign="top">Amphotericin B --&gt; Fluconazole</td>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>A few patients had more than one pathogen at baseline.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>Patients who did not have a 12-week assessment for any reason were considered a treatment failure.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">C. albicans</td>
<td class="Botrule" align="left" valign="top">46/107 (43%)</td>
<td class="Botrule" align="left" valign="top">30/63 (48%)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">C. tropicalis</td>
<td class="Botrule" align="left" valign="top">17/53 (32%)</td>
<td class="Botrule" align="left" valign="top">1/16 (6%)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">C. parapsilosis</td>
<td class="Botrule" align="left" valign="top">24/45 (53%)</td>
<td class="Botrule" align="left" valign="top">10/19 (53%)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">C. glabrata</td>
<td class="Botrule" align="left" valign="top">12/36 (33%)</td>
<td class="Botrule" align="left" valign="top">7/21 (33%)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">C. krusei</td>
<td class="Botrule" align="left" valign="top">1/4</td>
<td class="Botrule" align="left" valign="top">0/1</td>
</tr>
</tbody>
</table>
<p>In a secondary analysis, which counted DRC-assessed successes at any time point (EOT, or 2, 6, or 12 weeks after EOT), the response rates were 65% for voriconazole and 71% for the regimen of amphotericin B followed by fluconazole.</p>
<p>In Studies 608 and 309/604 (non-comparative study in patients with invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> who were refractory to, or intolerant of, other antifungal agents), voriconazole was evaluated in 35 patients with deep tissue <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. A favorable response was seen in 4 of 7 patients with intraabdominal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 5 of 6 patients with kidney and bladder wall <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 3 of 3 patients with deep tissue <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infection</span>, 1 of 2 patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>/pleural space <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 2 of 4 patients with <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span>, 1 of 1 patients with mixed intraabdominal and pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 1 of 2 patients with suppurative <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, 1 of 3 patients with hepatosplenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 1 of 5 patients with <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>, 0 of 1 with liver <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and 0 of 1 with cervical lymph node <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aab178dd-144e-415f-8ede-d0d15c3a7cdf"></a><a name="section-5.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></h2>
<p class="First">The efficacy of oral voriconazole 200 mg bid compared to oral fluconazole 200 mg od in the primary treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> was demonstrated in Study 150-305, a double-blind, double-dummy study in immunocompromised patients with endoscopically-proven <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>. Patients were treated for a median of 15 days (range 1 to 49 days). Outcome was assessed by repeat endoscopy at end of treatment (EOT). A successful response was defined as a normal endoscopy at EOT or at least a 1 grade improvement over baseline endoscopic score. For patients in the Intent to Treat (ITT) population with only a baseline endoscopy, a successful response was defined as symptomatic cure or improvement at EOT compared to baseline.Voriconazole and fluconazole (200 mg od) showed comparable efficacy rates against <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, as presented in Table 9.</p>
<a name="id_c07c50db-9fbf-4cd9-844b-1132f64d6786"></a><table width="344.000">
<caption><span>Table 9 Success Rates in Patients Treated for <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></span></caption>
<col align="left" width="25.0%">
<col align="left" width="25.0%">
<col align="left" width="25.0%">
<col align="left" width="25.0%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="top">Population</td>
<td class="Rrule" align="left" valign="top">Voriconazole</td>
<td class="Rrule" align="left" valign="top">Fluconazole</td>
<td class="Botrule" align="left" valign="top">Difference % (95% CI)<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Confidence Interval for the difference (Voriconazole – Fluconazole) in success rates.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>PP (Per Protocol) patients had confirmation of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> by endoscopy, received at least 12 days of treatment, and had a repeat endoscopy at EOT (end of treatment). </dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>ITT (Intent to Treat) patients without endoscopy or clinical assessment at EOT were treated as failures.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">PP<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a>
</td>
<td class="Botrule" align="left" valign="top">113/115 (98.2%)</td>
<td class="Botrule" align="left" valign="top">134/141 (95.0%)</td>
<td class="Botrule" align="left" valign="top">3.2 (-1.1, 7.5)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">ITT<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Botrule" align="left" valign="top">175/200 (87.5%)</td>
<td class="Botrule" align="left" valign="top">171/191 (89.5%)</td>
<td class="Botrule" align="left" valign="top">-2.0 (-8.3, 4.3)</td>
</tr>
</tbody>
</table>
<p>Microbiologic success rates by <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species are presented in Table 10.</p>
<a name="id_16d9cec4-1128-43be-9488-d8faf14c7115"></a><table width="430.000">
<caption><span>Table 10 Clinical and mycological outcome by baseline pathogen in patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> (Study 150–305).</span></caption>
<col align="left" width="13.0%">
<col align="center" width="20.9%">
<col align="center" width="22.1%">
<col align="center" width="20.9%">
<col align="center" width="23.0%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" rowspan="3" valign="top">Pathogen<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">Voriconazole</td>
<td class="Botrule" align="left" colspan="2" valign="top">Fluconazole</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Favorable endoscopic response<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">Mycological eradication<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">Favorable endoscopic response<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Botrule" align="left" valign="top">Mycological eradication<a href="#footnote-19" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top">Success/Total (%)</td>
<td class="Rrule" align="left" valign="top">Eradication/Total (%)</td>
<td class="Rrule" align="left" valign="top">Success/Total (%)</td>
<td class="Botrule" align="left" valign="top">Eradication/Total (%)</td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Some patients had more than one species isolated at baseline</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Patients with endoscopic and/or mycological assessment at end of therapy</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">C. albicans</td>
<td class="Botrule" align="left" valign="top">134/140 (96%)</td>
<td class="Botrule" align="left" valign="top">90/107 (84%)</td>
<td class="Botrule" align="left" valign="top">147/156 (94%)</td>
<td class="Botrule" align="left" valign="top">91/115 (79%)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">C. glabrata</td>
<td class="Botrule" align="left" valign="top">8/8 (100%)</td>
<td class="Botrule" align="left" valign="top">4/7 (57%)</td>
<td class="Botrule" align="left" valign="top">4/4 (100%)</td>
<td class="Botrule" align="left" valign="top">1/4 (25%)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">C. krusei</td>
<td class="Botrule" align="left" valign="top">1/1</td>
<td class="Botrule" align="left" valign="top">1/1</td>
<td class="Botrule" align="left" valign="top">2/2 (100%)</td>
<td class="Botrule" align="left" valign="top">0/0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd012b41-f20b-401c-96a8-54c00808e321"></a><a name="section-5.7"></a><p></p>
<h2>Other Serious Fungal Pathogens</h2>
<p class="First">In pooled analyses of patients, voriconazole was shown to be effective against the following additional fungal pathogens:</p>
<p><span class="Italics">Scedosporium apiospermum</span> - Successful response to voriconazole therapy was seen in 15 of 24 patients (63%). Three of these patients relapsed within 4 weeks, including 1 patient with pulmonary, skin and <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infections</span>, 1 patient with cerebral disease, and 1 patient with <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span>. Ten patients had evidence of cerebral disease and 6 of these had a successful outcome (1 relapse). In addition, a successful response was seen in 1 of 3 patients with mixed organism <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p><span class="Italics">Fusarium</span> spp. - Nine of 21 (43%) patients were successfully treated with voriconazole. Of these 9 patients, 3 had <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infections</span>, 1 had an eye and blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 1 had a <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span>, 1 had a blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> alone, 2 had <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infections</span>, and 1 had disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (pulmonary, skin, hepatosplenic). Three of these patients (1 with disseminated disease, 1 with an <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span> and 1 with a blood <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) had <span class="Italics">Fusarium solani</span> and were complete successes. Two of these patients relapsed, 1 with a <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span> and profound <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and 1 post surgical patient with blood and <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infections</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_b15e4865-d4ed-45fd-bc5e-d1c8c3b79aee"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">VFEND is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to voriconazole or its excipients. There is no information regarding cross-sensitivity between VFEND (voriconazole) and other azole antifungal agents. Caution should be used when prescribing VFEND to patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other azoles.</p>
<p>Coadministration of the CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide or quinidine with VFEND are contraindicated since increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span> (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Coadministration of VFEND with sirolimus is contraindicated because VFEND significantly increases sirolimus concentrations in healthy subjects (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Coadministration of VFEND with rifampin, carbamazepine and long-acting barbiturates is contraindicated since these drugs are likely to decrease plasma voriconazole concentrations significantly (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Coadministration of VFEND with high-dose ritonavir (400 mg Q12h) is contraindicated because ritonavir (400 mg Q12h) significantly decreases plasma voriconazole concentrations in healthy subjects. Coadministration of voriconazole and low-dose ritonavir (100 mg Q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Coadministration of VFEND with rifabutin is contraindicated since VFEND significantly increases rifabutin plasma concentrations and rifabutin also significantly decreases voriconazole plasma concentrations (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Coadministration of VFEND with ergot alkaloids (ergotamine and dihydroergotamine) is contraindicated because VFEND may increase the plasma concentration of ergot alkaloids, which may lead to <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>.</p>
<p>Coadministration of VFEND with St. John's Wort is contraindicated (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6894b53-da25-46f4-9a42-4d8913f3e08b"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">VISUAL DISTURBANCES</span></h2>
<p class="First"><span class="Bold">The effect of VFEND on visual function is not known if treatment continues beyond 28 days.</span> There have been post-marketing reports of prolonged visual adverse events, including <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>. These events occurred primarily in severely ill patients who had underlying conditions and/or concomitant medications which may have caused or contributed to these events. If treatment continues beyond 28 days, visual function including visual acuity, visual field and color perception should be monitored <span class="Bold">(see <a href="#i4i_info_patients_id_ab5a8ab6-722a-4535-858f-87e735c078f6">PRECAUTIONS – Information for Patients</a> and <a href="#i4i_section_id_d6894b53-da25-46f4-9a42-4d8913f3e08b">ADVERSE REACTIONS – <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbances</span></a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b7f784f-7e35-4703-848f-2cbd56b7b574"></a><a name="section-7.2"></a><p></p>
<h2>HEPATIC TOXICITY</h2>
<p class="First"><span class="Bold">In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with VFEND (including clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> and <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span>, including fatalities).</span> Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly <span class="product-label-link" type="condition" conceptid="4044013" conceptname="Hematologic neoplasm">hematological malignancy</span>). Hepatic reactions, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy <span class="Bold">(see <a href="#i4i_lab_tests_id_a09cb16c-0600-467c-aaf8-ebf93569b576">PRECAUTIONS – Laboratory Tests</a> and <a href="#i4i_section_id_ee1c558b-a6c1-441b-b673-b520fe3aafe5">ADVERSE REACTIONS – Clinical Laboratory Values</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c335cce-b598-4edb-bec4-d0b720c8caa8"></a><a name="section-7.3"></a><p></p>
<h2>Monitoring of hepatic function</h2>
<p class="First">Liver function tests should be evaluated at the start of and during the course of VFEND therapy. Patients who develop <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> during VFEND therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of VFEND must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to VFEND (see <a href="#i4i_lab_tests_id_a09cb16c-0600-467c-aaf8-ebf93569b576">PRECAUTIONS - Laboratory Tests</a>, <a href="#i4i_section_id_a197dd6f-9575-4548-83bc-b9d0459bbeb3">DOSAGE AND ADMINISTRATION - Dosage Adjustment</a>, <a href="#i4i_section_id_ee1c558b-a6c1-441b-b673-b520fe3aafe5">ADVERSE REACTIONS - Clinical Laboratory Tests)</a>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_89a7f980-5843-4aec-82a3-67375539f46d"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy Category D</h2>
<p class="First">Voriconazole can cause fetal harm when administered to a pregnant woman.</p>
<p>Voriconazole was teratogenic in rats (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span>, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>/<span class="product-label-link" type="condition" conceptid="194408" conceptname="Hydroureter">hydroureter</span>) from 10 mg/kg (0.3 times the recommended maintenance dose (RMD) on a mg/m<span class="Sup">2</span> basis) and embryotoxic in rabbits at 100 mg/kg (6 times the RMD). Other effects in rats included reduced ossification of sacral and caudal vertebrae, skull, pubic and hyoid bone, supernumerary ribs, anomalies of the sternebrae and dilatation of the ureter/renal pelvis. Plasma estradiol in pregnant rats was reduced at all dose levels. Voriconazole treatment in rats produced increased gestational length and dystocia, which were associated with increased perinatal pup mortality at the 10 mg/kg dose. The effects seen in rabbits were an increased embryomortality, reduced fetal weight and increased incidences of skeletal variations, cervical ribs and extrasternebral ossification sites.</p>
<p>If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d1784e2-9a0c-46ce-808d-79f674abd2bd"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4098477" conceptname="Glucose-galactose malabsorption">Galactose intolerance</span></h2>
<p class="First">VFEND tablets contain lactose and should not be given to patients with rare hereditary problems of <span class="product-label-link" type="condition" conceptid="4098477" conceptname="Glucose-galactose malabsorption">galactose intolerance</span>, Lapp <span class="product-label-link" type="condition" conceptid="4029736" conceptname="Lactase deficiency">lactase deficiency</span> or glucose-galactose <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_58a12870-2af2-4332-88a5-5090552c23c1"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_9e3cf5f9-011a-4e96-932b-55721053cae7"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">(See <a href="#i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735">WARNINGS</a>, <a href="#i4i_dosage_admin_id_40f5361c-a556-46cc-8ae1-92f7b209c2be">DOSAGE AND ADMINISTRATION</a>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_184ab865-ba69-4514-8b15-00c634c08881"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> and QT Prolongation</h2>
<p class="First">Some azoles, including voriconazole, have been associated with prolongation of the QT interval on the electrocardiogram. During clinical development and post-marketing surveillance, there have been rare cases of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, (including <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> such as <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span>), <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrests</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden deaths</span> in patients taking voriconazole. These cases usually involved seriously ill patients with multiple confounding risk factors, such as history of cardiotoxic chemotherapy, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and concomitant medications that may have been contributory.</p>
<p>Voriconazole should be administered with caution to patients with these potentially proarrhythmic conditions.</p>
<p>Rigorous attempts to correct potassium, magnesium and calcium should be made before starting voriconazole (see <a href="#i4i_section_id_b3022d4d-4f55-4def-bbb5-de22bc7de92c">CLINICAL PHARMACOLOGY- Pharmacokinetic-Pharmacodynamic Relationships - Electrocardiogram</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1f39165-9bfa-42b9-abb1-39db0d5d1d17"></a><a name="section-8.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">Infusion Related Reactions</span></h2>
<p class="First">During infusion of the intravenous formulation of voriconazole in healthy subjects, anaphylactoid-type reactions, including <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, faintness, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, have occurred uncommonly. Symptoms appeared immediately upon initiating the infusion. Consideration should be given to stopping the infusion should these reactions occur.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ab5a8ab6-722a-4535-858f-87e735c078f6"></a><a name="section-8.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised:</p>
<ul>
<li>that VFEND Tablets or Oral Suspension should be taken at least one hour before, or one hour following, a meal.</li>
<li><span class="Bold">that they should not drive at night while taking VFEND. VFEND may cause changes to vision, including blurring and/or <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>.</span></li>
<li><span class="Bold">that they should avoid potentially hazardous tasks, such as driving or operating machinery if they perceive any change in vision.</span></li>
<li>that strong, direct sunlight should be avoided during VFEND therapy.</li>
<li>that VFEND for Oral Suspension contains sucrose and is not recommended for patients with rare hereditary problems of fructose intolerance, sucrase-isomaltase deficiency or glucose-galactose <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_a09cb16c-0600-467c-aaf8-ebf93569b576"></a><a name="section-8.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte disturbances</span> such as <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> and <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> should be corrected prior to initiation of VFEND therapy.</p>
<p>Patient management should include laboratory evaluation of renal (particularly serum creatinine) and hepatic function (particularly liver function tests and bilirubin).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d"></a><a name="section-8.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Tables 11 and 12 provide a summary of significant drug interactions with voriconazole that either have been studied <span class="Italics">in vivo</span> (clinically) or that may be expected to occur based on results of <span class="Italics">in vitro</span> metabolism studies with human liver microsomes. For more details, see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>.</p>
<a name="id_87dca7d7-d62b-4cfb-abcf-1ab118151a8e"></a><table width="430.000">
<caption><span>Table 11: Effect of Other Drugs on Voriconazole Pharmacokinetics</span></caption>
<col align="left" width="34.0%">
<col align="center" width="33.0%">
<col align="center" width="33.0%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="center" valign="top">Drug/Drug Class<br>(Mechanism of Interaction by the Drug)</td>
<td class="Rrule" align="left" valign="top">Voriconazole Plasma Exposure<br>(C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> after<br>200 mg Q12h)</td>
<td class="Rrule" align="left" valign="top">Recommendations for Voriconazole<br>Dosage Adjustment/Comments</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Results based on <span class="Italics">in vivo</span> clinical studies generally following repeat oral dosing with 200 mg Q12h voriconazole to healthy subjects</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>Results based on <span class="Italics">in vivo</span> clinical study following repeat oral dosing with 400 mg Q12h for 1 day, then 200 mg Q12h for at least 2 days voriconazole to healthy subjects</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">‡</a></dt>
<dd>Non-Nucleoside Reverse Transcriptase Inhibitors</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Botrule Lrule" align="left" valign="top">Rifampin<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a>, and Rifabutin<a href="#footnote-20" class="Sup">*</a><br>(CYP450 Induction)</td>
<td class="Botrule" align="left" valign="top">Significantly Reduced</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Efavirenz<a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a><br>(CYP450 Induction) </td>
<td align="left" valign="top">Significantly Reduced</td>
<td class="Rrule" align="left" valign="top">When voriconazole is coadministered with efavirenz, voriconazole maintenance dose should be increased to 400 mg Q12h and efavirenz should be decreased to 300 mg Q24h (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_a7dc4ff3-a754-4ca9-a070-ff5efd1049b0">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_section_id_a197dd6f-9575-4548-83bc-b9d0459bbeb3">DOSAGE AND ADMINISTRATION-Dosage Adjustment</a>)</span>
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">High-dose Ritonavir (400mg Q12h)<a href="#footnote-21" class="Sup">†</a><br>(CYP450 Induction)</td>
<td align="left" valign="top">Significantly Reduced</td>
<td class="Rrule" align="left" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">Low-dose Ritonavir (100mg Q12h)<a href="#footnote-21" class="Sup">†</a><br>(CYP450 Induction)</td>
<td align="left" valign="middle">Reduced</td>
<td class="Rrule" align="left" valign="bottom">Coadministration of voriconazole and low-dose ritonavir (100 mg Q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Carbamazepine <br>(CYP450 Induction)</td>
<td class="Botrule" align="left" valign="top">Not Studied In Vivo or In Vitro, but Likely to Result in Significant Reduction</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Long Acting Barbiturates <br>(CYP450 Induction)</td>
<td class="Botrule" align="left" valign="top">Not Studied In Vivo or In Vitro, but Likely to Result in Significant Reduction</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Phenytoin<a href="#footnote-20" class="Sup">*</a><br>(CYP450 Induction)</td>
<td class="Botrule" align="left" valign="top">Significantly Reduced</td>
<td class="Botrule Rrule" align="left" valign="top">Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV every 12 hrs or from 200 mg to 400 mg orally every 12 hrs (100 mg to 200 mg orally every 12 hrs in patients weighing less than 40 kg)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">St. John's Wort<br>(CYP450 inducer; P-gp inducer)</td>
<td class="Botrule" align="left" valign="top">Significantly Reduced</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Oral Contraceptives<a href="#footnote-20" class="Sup">*</a> containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition)</td>
<td align="left" valign="top">Increased</td>
<td class="Rrule" align="left" valign="top">Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Other HIV Protease Inhibitors <br>(CYP3A4 Inhibition)</td>
<td class="Botrule" align="left" valign="top">In Vivo Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure<br><br>In Vitro Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure) </td>
<td class="Botrule Rrule" align="left" valign="top">No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir<br><br>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Other NNRTIs<a name="footnote-reference-22" href="#footnote-22" class="Sup">‡</a><br>(CYP3A4 Inhibition or CYP450 Induction) </td>
<td align="left" valign="top">In Vitro Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)</td>
<td class="Rrule" align="left" valign="top">Frequent monitoring for adverse events and toxicity related to voriconazole</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule" align="left" valign="top"></td>
<td align="left" valign="top">
<br>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure) </td>
<td class="Rrule" align="left" valign="top">
<br>Careful assessment of voriconazole effectiveness</td>
</tr>
</tbody>
</table>
<a name="id_8d85de73-0d00-444c-bf64-03f27504ceb9"></a><table width="430.000">
<caption><span>Table 12: Effect of Voriconazole on Pharmacokinetics of Other Drugs</span></caption>
<col align="left" width="33.0%">
<col align="center" width="34.0%">
<col align="center" width="33.0%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="center" valign="top">Drug/Drug Class<br>(Mechanism of Interaction by Voriconazole) </td>
<td class="Rrule" align="center" valign="top">Drug Plasma Exposure<br>(C<span class="Sub">max</span> and AUC<span class="Sub">τ</span>)</td>
<td class="Botrule" align="center" valign="top">Recommendations for Drug Dosage Adjustment/Comments</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">†</a></dt>
<dd>Results based on in vivo clinical study following repeat oral dosing with 400 mg Q12h for 1 day, then 200 mg Q12h for at least 2 days voriconazole to healthy subjects</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">‡</a></dt>
<dd>Results based on in vivo clinical study following repeat oral dosing with 400 mg Q12h for 1 day, then 200 mg Q12h for 4 days voriconazole to subjects receiving a methadone maintenance dose (30–100 mg QD)</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">§</a></dt>
<dd>Non-Nucleoside Reverse Transcriptase Inhibitors</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Sirolimus<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a><br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">Significantly Increased</td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Rifabutin<a href="#footnote-23" class="Sup">*</a><br>(CYP3A4 Inhibition)</td>
<td class="Botrule" align="left" valign="top">Significantly Increased</td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td align="left" valign="top">Efavirenz<a name="footnote-reference-24" href="#footnote-24" class="Sup">†</a><br>(CYP3A4 Inhibition)</td>
<td align="left" valign="top">Significantly Increased</td>
<td align="left" valign="top">When voriconazole is coadministered with efavirenz, voriconazole maintenance dose should be increased to 400 mg Q12h and efavirenz should be decreased to 300 mg Q24h (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_a7dc4ff3-a754-4ca9-a070-ff5efd1049b0">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_section_id_a197dd6f-9575-4548-83bc-b9d0459bbeb3">DOSAGE AND ADMINISTRATION-Dosage Adjustment</a>)</span>
</td>
</tr>
<tr>
<td align="left" valign="top">High-dose Ritonavir (400 mg Q12h)<a href="#footnote-24" class="Sup">†</a>(CYP3A4 Inhibition)</td>
<td align="left" valign="top">No Significant Effect of Voriconazole on Ritonavir C<span class="Sub">max</span> or AUC<span class="Sub">τ</span>
</td>
<td align="left" valign="top">
<span class="Bold">Contraindicated</span> because of significant reduction of voriconazole C<span class="Sub">max</span> and AUC<span class="Sub">τ</span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Low-dose Ritonavir (100mg Q12h)<a href="#footnote-24" class="Sup">†</a>
</td>
<td class="Botrule" align="left" valign="top">Slight Decrease in Ritonavir C<span class="Sub">max</span> and AUC<span class="Sub">τ</span>
</td>
<td class="Botrule" align="left" valign="top"> Coadministration of voriconazole and low-dose ritonavir (100 mg Q12h) should be avoided (due to the reduction in voriconazole C<span class="Sub">max</span> and AUC<span class="Sub">τ</span>) unless an assessment of the benefit/risk to the patient justifies the use of voriconazole </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Terfenadine, Astemizole, Cisapride, Pimozide, Quinidine<br>(CYP3A4 Inhibition)</td>
<td class="Botrule" align="left" valign="top">Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Contraindicated</span> because of potential for QT prolongation and rare occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ergot Alkaloids<br>(CYP450 Inhibition)</td>
<td class="Botrule" align="left" valign="top">Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased</td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Contraindicated</span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Cyclosporine<a href="#footnote-23" class="Sup">*</a><br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">AUC<span class="Sub">τ</span> Significantly Increased; No Significant Effect on C<span class="Sub">max</span>
</td>
<td class="Botrule" align="left" valign="top">When initiating therapy with VFEND in patients already receiving cyclosporine, reduce the cyclosporine dose to one-half of the starting dose and follow with frequent monitoring of cyclosporine blood levels. Increased cyclosporine levels have been associated with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. When VFEND is discontinued, cyclosporine concentrations must be frequently monitored and the dose increased as necessary.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Methadone<a name="footnote-reference-25" href="#footnote-25" class="Sup">‡</a> (CYP3A4 Inhibition)</td>
<td class="Botrule" align="left" valign="top">Increased</td>
<td class="Botrule" align="left" valign="top">Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Alfentanil (CYP3A4 Inhibition)</td>
<td class="Botrule" align="left" valign="top">Significantly Increased</td>
<td class="Botrule" align="left" valign="top">Reduction in the dose of alfentanil and other opiates metabolized by CYP3A4 (e.g., sufentanil) should be considered when coadministered with VFEND. A longer period for monitoring respiratory and other opiate-associated adverse events may be necessary (see <a href="#i4i_section_id_0b102266-5d45-40d6-8cb3-6e9b3d623950">CLINICAL PHARMACOLOGY - Drug Interactions</a>).</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Tacrolimus<a href="#footnote-23" class="Sup">*</a><br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">Significantly Increased</td>
<td class="Botrule" align="left" valign="top">When initiating therapy with VFEND in patients already receiving tacrolimus, reduce the tacrolimus dose to one-third of the starting dose and follow with frequent monitoring of tacrolimus blood levels. Increased tacrolimus levels have been associated with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. When VFEND is discontinued, tacrolimus concentrations must be frequently monitored and the dose increased as necessary.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Phenytoin<a href="#footnote-23" class="Sup">*</a><br>(CYP2C9 Inhibition) </td>
<td class="Botrule" align="left" valign="top">Significantly Increased</td>
<td class="Botrule" align="left" valign="top">Frequent monitoring of phenytoin plasma concentrations and frequent monitoring of adverse effects related to phenytoin.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Oral Contraceptives containing ethinyl estradiol and norethindrone (CYP3A4 Inhibition)<a href="#footnote-24" class="Sup">†</a>
</td>
<td class="Botrule" align="left" valign="top">Increased</td>
<td class="Botrule" align="left" valign="top">Monitoring for adverse events related to oral contraceptives is recommended during coadministration.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Warfarin<a href="#footnote-23" class="Sup">*</a><br>(CYP2C9 Inhibition) </td>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time Significantly Increased</td>
<td class="Botrule" align="left" valign="top">Monitor PT or other suitable anti-coagulation tests. Adjustment of warfarin dosage may be needed.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Omeprazole<a href="#footnote-23" class="Sup">*</a><br>(CYP2C19/3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">Significantly Increased</td>
<td class="Botrule" align="left" valign="top">When initiating therapy with VFEND in patients already receiving omeprazole doses of 40 mg or greater, reduce the omeprazole dose by one-half. The metabolism of other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of other proton pump inhibitors. </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Other HIV Protease Inhibitors<br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">In Vivo Studies Showed No Significant Effects on Indinavir Exposure<br><br>In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br>(Increased Plasma Exposure) </td>
<td class="Botrule" align="left" valign="top">No dosage adjustment for indinavir when coadministered with VFEND<br><br>Frequent monitoring for adverse events and toxicity related to other HIV protease inhibitors </td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Other NNRTIs<a name="footnote-reference-26" href="#footnote-26" class="Sup">§</a><br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for Voriconazole to Inhibit Metabolism of Other NNRTIs<br>(Increased Plasma Exposure) </td>
<td class="Botrule" align="left" valign="top">Frequent monitoring for adverse events and toxicity related to NNRTI</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Benzodiazepines<br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br>(Increased Plasma Exposure) </td>
<td class="Botrule" align="left" valign="top">Frequent monitoring for adverse events and toxicity (i.e., prolonged sedation) related to benzodiazepines metabolized by CYP3A4 (e.g., midazolam, triazolam, alprazolam). Adjustment of benzodiazepine dosage may be needed.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">HMG-CoA Reductase Inhibitors (Statins)<br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br>(Increased Plasma Exposure) </td>
<td class="Botrule" align="left" valign="top">Frequent monitoring for adverse events and toxicity related to statins. Increased statin concentrations in plasma have been associated with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Adjustment of the statin dosage may be needed.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Dihydropyridine Calcium Channel Blockers<br>(CYP3A4 Inhibition) </td>
<td class="Botrule" align="left" valign="top">In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br>(Increased Plasma Exposure) </td>
<td class="Botrule" align="left" valign="top">Frequent monitoring for adverse events and toxicity related to calcium channel blockers. Adjustment of calcium channel blocker dosage may be needed.</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Sulfonylurea Oral Hypoglycemics<br>(CYP2C9 Inhibition) </td>
<td class="Botrule" align="left" valign="top">Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased</td>
<td class="Botrule" align="left" valign="top">Frequent monitoring of blood glucose and for signs and symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Adjustment of oral hypoglycemic drug dosage may be needed.</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Vinca Alkaloids<br>(CYP3A4 Inhibition)</td>
<td class="Botrule" align="left" valign="top">Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased</td>
<td class="Botrule" align="left" valign="top">Frequent monitoring for adverse events and toxicity (i.e., <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>) related to vinca alkaloids. Adjustment of vinca alkaloid dosage may be needed.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec1f0f1e-e511-46a0-9325-419bc1eb6b3b"></a><a name="section-8.7"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child-Pugh Class A and B) receiving VFEND (see <a href="#i4i_section_id_dadae99c-c051-41ea-b6b7-07efdaceeec6">CLINICAL PHARMACOLOGY - <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a>, <a href="#i4i_section_id_a835b637-c69a-4baa-88fa-2a6f50a5fb8e">DOSAGE and ADMINISTRATION - <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a>).</p>
<p>VFEND has not been studied in patients with severe cirrhosis (Child-Pugh Class C). VFEND has been associated with elevations in liver function tests and clinical signs of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, such as <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and should only be used in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> if the benefit outweighs the potential risk. Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> must be carefully monitored for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e44aecbe-f465-4935-b28c-4649b5320417"></a><a name="section-8.8"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">In patients with moderate to severe renal dysfunction (creatinine clearance &lt;50 mL/min), accumulation of the intravenous vehicle, SBECD, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the benefit/risk to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients, and if increases occur, consideration should be given to changing to oral voriconazole therapy (see <a href="#i4i_section_id_a835b637-c69a-4baa-88fa-2a6f50a5fb8e">CLINICAL PHARMACOLOGY - <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a>, <a href="#i4i_section_id_a835b637-c69a-4baa-88fa-2a6f50a5fb8e">DOSAGE AND ADMINISTRATION - <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77275ef9-f29d-4c74-b7b7-fbec0d92b0eb"></a><a name="section-8.9"></a><p></p>
<h2>Renal Adverse Events</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> has been observed in severely ill patients undergoing treatment with VFEND. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and have concurrent conditions that may result in decreased renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_070472ab-3258-4dd8-a13b-5add84af096e"></a><a name="section-8.10"></a><p></p>
<h2>Monitoring of Renal Function</h2>
<p class="First">Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_705d7667-c3fb-40e4-a9fe-7388782d54eb"></a><a name="section-8.11"></a><p></p>
<h2>Monitoring of Pancreatic Function</h2>
<p class="First">Adults and children with risk factors for <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> (e.g., recent chemotherapy, hematopoietic stem cell transplantation [HSCT]) should be monitored for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> during VFEND treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f4450ef5-86d9-48e9-a7ef-1396814b29d1"></a><a name="section-8.12"></a><p></p>
<h2>Dermatological Reactions</h2>
<p class="First">Patients have rarely developed serious cutaneous reactions, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, during treatment with VFEND. If patients develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, they should be monitored closely and consideration given to discontinuation of VFEND. VFEND has been infrequently associated with <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>, especially during long-term therapy. It is recommended that patients avoid strong, direct sunlight during VFEND therapy.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ab5d7231-04b1-4948-9065-49cc584b2bb7"></a><a name="section-8.13"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Two-year carcinogenicity studies were conducted in rats and mice. Rats were given oral doses of 6, 18 or 50 mg/kg voriconazole, or 0.2, 0.6, or 1.6 times the recommended maintenance dose (RMD) on a mg/m<span class="Sup">2</span> basis. <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatocellular adenomas</span> were detected in females at 50 mg/kg and hepatocellular carcinomas were found in males at 6 and 50 mg/kg. Mice were given oral doses of 10, 30 or 100 mg/kg voriconazole, or 0.1, 0.4, or 1.4 times the RMD on a mg/m<span class="Sup">2</span> basis. In mice, <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> were detected in males and females and hepatocellular carcinomas were detected in males at 1.4 times the RMD of voriconazole.</p>
<p>Voriconazole demonstrated clastogenic activity (mostly chromosome breaks) in human lymphocyte cultures <span class="Italics">in vitro</span>. Voriconazole was not genotoxic in the Ames assay, CHO assay, the mouse micronucleus assay or the DNA repair test (Unscheduled DNA Synthesis assay).</p>
<p>Voriconazole produced a reduction in the pregnancy rates of rats dosed at 50 mg/kg, or 1.6 times the RMD. This was statistically significant only in the preliminary study and not in a larger fertility study.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_6f9fd8ed-1b97-4ae9-9b94-30890190a763"></a><a name="section-8.14"></a><p></p>
<h2>Teratogenic Effects</h2>
<p class="First">Pregnancy category D (see <a href="#i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1fd08f33-a3db-4b48-8305-b4bd4873d2f9"></a><a name="section-8.15"></a><p></p>
<h2>Women of Childbearing Potential</h2>
<p class="First">Women of childbearing potential should use effective contraception during treatment. The coadministration of voriconazole with the oral contraceptive, Ortho-Novum® (35 mcg ethinyl estradiol and 1 mg norethindrone), results in an interaction between these two drugs, but is unlikely to reduce the contraceptive effect. (see CLINICAL PHARMACOLOGY-Drug Interactions-Oral Contraceptives; <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS-Drug Interactions</a>)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0b98aa3e-9796-4e19-9b45-b4523783a114"></a><a name="section-8.16"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">The excretion of voriconazole in breast milk has not been investigated. VFEND should not be used by nursing mothers unless the benefit clearly outweighs the risk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_3a3cc1af-d3cf-430c-896a-96468b2b25ad"></a><a name="section-8.17"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 years have not been established.</p>
<p>A total of 22 patients aged 12–18 years with invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> were included in the therapeutic studies. Twelve out of 22 (55%) patients had successful response after treatment with a maintenance dose of voriconazole 4 mg/kg Q12h<span class="Bold">.</span></p>
<p>Sparse plasma sampling for pharmacokinetics in adolescents was conducted in the therapeutic studies (see CLINICAL PHARMACOLOGY - Pharmacokinetics, General Pharmacokinetic Characteristics).</p>
<p>There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> in pediatric patients. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_6954c958-f2d4-4d75-846e-92ad5ec3ad13"></a><a name="section-8.18"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In multiple dose therapeutic trials of voriconazole, 9.2% of patients were ≥ 65 years of age and 1.8% of patients were ≥ 75 years of age. In a study in healthy subjects, the systemic exposure (AUC) and peak plasma concentrations (C<span class="Sub">max</span>) were increased in elderly males compared to young males. Pharmacokinetic data obtained from 552 patients from 10 voriconazole therapeutic trials showed that voriconazole plasma concentrations in the elderly patients were approximately 80% to 90% higher than those in younger patients after either IV or oral administration. However, the overall safety profile of the elderly patients was similar to that of the young so no dosage adjustment is recommended (see <a href="#i4i_section_id_8979888c-fa68-4cc0-acae-c6eb14ff086d">CLINICAL PHARMACOLOGY - Pharmacokinetics in Special Populations</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_cfa6573a-2c40-4c6c-a657-dc98fae1736d"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3d9653d-e7b4-4dc3-8b84-babab70ef3cc"></a><a name="section-9.1"></a><p></p>
<h2>Overview</h2>
<p class="First">The most frequently reported adverse events (all causalities) in the therapeutic trials were <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>. The treatment-related adverse events which most often led to discontinuation of voriconazole therapy were elevated liver function tests, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (see <a href="#i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735">hepatic toxicity under WARNINGS</a> and discussion of Clinical Laboratory Values and dermatological and visual adverse events below).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_235e647e-c899-401c-bdb2-d40227db8bac"></a><a name="section-9.2"></a><p></p>
<h2>Discussion of Adverse Reactions</h2>
<p class="First">The data described in Table 13 reflect exposure to voriconazole in 1655 patients in the therapeutic studies. This represents a heterogeneous population, including immunocompromised patients, e.g., patients with <span class="product-label-link" type="condition" conceptid="4044013" conceptname="Hematologic neoplasm">hematological malignancy</span> or HIV and non-neutropenic patients. This subgroup does not include healthy subjects and patients treated in the compassionate use and non-therapeutic studies. This patient population was 62% male, had a mean age of 46 years (range 11–90, including 51 patients aged 12–18 years), and was 78% white and 10% black. In the initial regulatory filing, 561 patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over six months. Table 13 includes all adverse events which were reported at an incidence of ≥2% during voriconazole therapy in the all therapeutic studies population, studies 307/602 and 608 combined, or study 305, as well as events of concern which occurred at an incidence of &lt;2%.</p>
<p>In study 307/602, 381 patients (196 on voriconazole, 185 on amphotericin B) were treated to compare voriconazole to amphotericin B followed by other licensed antifungal therapy in the primary treatment of patients with acute invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>. In study 608, 403 patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> were treated to compare voriconazole (272 patients) to the regimen of amphotericin B followed by fluconazole (131 patients). Study 305 evaluated the effects of oral voriconazole (200 patients) and oral fluconazole (191 patients) in the treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>. Laboratory test abnormalities for these studies are discussed under Clinical Laboratory Values below.</p>
<a name="id_62109431-76df-4097-b2d4-3c8bf0cd3b07"></a><table width="432.000">
<caption><span>Table 13 Treatment Emergent Adverse Events</span></caption>
<col align="left" width="19.9%">
<col align="center" width="15.0%">
<col align="center" width="15.0%">
<col align="center" width="10.0%">
<col align="center" width="15.0%">
<col align="center" width="15.0%">
<col align="center" width="10.0%">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="7" valign="top">Rate ≥ 2% on Voriconazole or Adverse Events of Concern in All Therapeutic Studies Population, Studies 307/602–608 Combined, or Study 305. Possibly Related to Therapy or Causality Unknown<a name="footnote-reference-27" href="#footnote-27" class="Sup">*</a>
</td></tr>
<tr>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">All Therapeutic Studies</td>
<td class="Botrule Rrule" align="left" colspan="3" valign="middle">Studies 307/602 and 608<br>(IV/ oral therapy)</td>
<td class="Botrule" align="left" colspan="2" valign="middle">Study 305<br>(oral therapy) </td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Voriconazole<br>N = 1655</td>
<td class="Botrule Rrule" align="left" valign="top">Voriconazole<br>N = 468</td>
<td class="Botrule Rrule" align="left" valign="top">Ampho B<a name="footnote-reference-28" href="#footnote-28" class="Sup">†</a><br>N=185</td>
<td class="Botrule Rrule" align="left" valign="top">Ampho B→ Fluconazole<br>N= 131</td>
<td class="Botrule Rrule" align="left" valign="top">Voriconazole<br>N = 200</td>
<td class="Botrule" align="left" valign="top">Fluconazole<br>N =191</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">N (%)</td>
<td class="Botrule Rrule" align="left" valign="top">N (%)</td>
<td class="Botrule Rrule" align="left" valign="top">N (%)</td>
<td class="Botrule Rrule" align="left" valign="top">N (%)</td>
<td class="Botrule Rrule" align="left" valign="top">N (%)</td>
<td class="Botrule" align="left" valign="top">N (%)</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"><br></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-27" href="#footnote-reference-27">*</a></dt>
<dd><span class="Bold">Study 307/602: invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>; Study 608: <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>; Study 305: <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span></span></dd>
<dt><a name="footnote-28" href="#footnote-reference-28">†</a></dt>
<dd>Amphotericin B followed by other licensed antifungal therapy</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">‡</a></dt>
<dd>See <a href="#i4i_section_id_d6894b53-da25-46f4-9a42-4d8913f3e08b">WARNINGS – <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbances</span></a>, <a href="#i4i_info_patients_id_ab5a8ab6-722a-4535-858f-87e735c078f6">PRECAUTIONS – Information for Patients</a>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"><span class="Bold">Special Senses<a name="footnote-reference-29" href="#footnote-29" class="Sup">‡</a></span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></td>
<td class="Botrule" align="left" valign="top">310 (18.7)</td>
<td class="Botrule" align="left" valign="top">63 (13.5)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">31 (15.5)</td>
<td class="Botrule" align="left" valign="top">8 (4.2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span></td>
<td class="Botrule" align="left" valign="top">37 (2.2)</td>
<td class="Botrule" align="left" valign="top">8 (1.7)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">5 (2.5)</td>
<td class="Botrule" align="left" valign="top">2 (1.0)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">Chromatopsia</span></td>
<td class="Botrule" align="left" valign="top">20 (1.2)</td>
<td class="Botrule" align="left" valign="top">2 (0.4)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">2 (1.0)</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Body as a Whole</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Botrule" align="left" valign="top">94 (5.7)</td>
<td class="Botrule" align="left" valign="top">8 (1.7)</td>
<td class="Botrule" align="left" valign="top">25 (13.5)</td>
<td class="Botrule" align="left" valign="top">5 (3.8)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Botrule" align="left" valign="top">61 (3.7)</td>
<td class="Botrule" align="left" valign="top">1 (0.2)</td>
<td class="Botrule" align="left" valign="top">36 (19.5)</td>
<td class="Botrule" align="left" valign="top">8 (6.1)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule" align="left" valign="top">49 (3.0)</td>
<td class="Botrule" align="left" valign="top">9 (1.9)</td>
<td class="Botrule" align="left" valign="top">8 (4.3)</td>
<td class="Botrule" align="left" valign="top">1 (0.8)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Cardiovascular System</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Botrule" align="left" valign="top">39 (2.4)</td>
<td class="Botrule" align="left" valign="top">6 (1.3)</td>
<td class="Botrule" align="left" valign="top">5 (2.7)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Digestive System</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule" align="left" valign="top">89 (5.4)</td>
<td class="Botrule" align="left" valign="top">18 (3.8)</td>
<td class="Botrule" align="left" valign="top">29 (15.7)</td>
<td class="Botrule" align="left" valign="top">2 (1.5)</td>
<td class="Botrule" align="left" valign="top">2 (1.0)</td>
<td class="Botrule" align="left" valign="top">3 (1.6)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule" align="left" valign="top">72 (4.4)</td>
<td class="Botrule" align="left" valign="top">15 (3.2)</td>
<td class="Botrule" align="left" valign="top">18 (9.7)</td>
<td class="Botrule" align="left" valign="top">1 (0.8)</td>
<td class="Botrule" align="left" valign="top">2 (1.0)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function tests abnormal</span></td>
<td class="Botrule" align="left" valign="top">45 (2.7)</td>
<td class="Botrule" align="left" valign="top">15 (3.2)</td>
<td class="Botrule" align="left" valign="top">4 (2.2)</td>
<td class="Botrule" align="left" valign="top">1 (0.8)</td>
<td class="Botrule" align="left" valign="top">6 (3.0)</td>
<td class="Botrule" align="left" valign="top">2 (1.0)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span></td>
<td class="Botrule" align="left" valign="top">17 (1.0)</td>
<td class="Botrule" align="left" valign="top">8 (1.7)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">1 (0.8)</td>
<td class="Botrule" align="left" valign="top">3 (1.5)</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Metabolic and Nutritional Systems</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Alkaline phosphatase increased</td>
<td class="Botrule" align="left" valign="top">59 (3.6)</td>
<td class="Botrule" align="left" valign="top">19 (4.1)</td>
<td class="Botrule" align="left" valign="top">4 (2.2)</td>
<td class="Botrule" align="left" valign="top">3 (2.3)</td>
<td class="Botrule" align="left" valign="top">10 (5.0)</td>
<td class="Botrule" align="left" valign="top">3 (1.6)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Hepatic enzymes increased</td>
<td class="Botrule" align="left" valign="top">30 (1.8)</td>
<td class="Botrule" align="left" valign="top">11 (2.4)</td>
<td class="Botrule" align="left" valign="top">5 (2.7)</td>
<td class="Botrule" align="left" valign="top">1 (0.8)</td>
<td class="Botrule" align="left" valign="top">3 (1.5)</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased</td>
<td class="Botrule" align="left" valign="top">31 (1.9)</td>
<td class="Botrule" align="left" valign="top">9 (1.9)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">1 (0.8)</td>
<td class="Botrule" align="left" valign="top">8 (4.0)</td>
<td class="Botrule" align="left" valign="top">2 (1.0)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">SGPT increased</td>
<td class="Botrule" align="left" valign="top">29 (1.8)</td>
<td class="Botrule" align="left" valign="top">9 (1.9)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
<td class="Botrule" align="left" valign="top">2 (1.5)</td>
<td class="Botrule" align="left" valign="top">6 (3.0)</td>
<td class="Botrule" align="left" valign="top">2 (1.0)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Botrule" align="left" valign="top">26 (1.6)</td>
<td class="Botrule" align="left" valign="top">3 (0.6)</td>
<td class="Botrule" align="left" valign="top">36 (19.5)</td>
<td class="Botrule" align="left" valign="top">16 (12.2)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Bilirubinemia</span></td>
<td class="Botrule" align="left" valign="top">15 (0.9)</td>
<td class="Botrule" align="left" valign="top">5 (1.1)</td>
<td class="Botrule" align="left" valign="top">3 (1.6)</td>
<td class="Botrule" align="left" valign="top">2 (1.5)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Creatinine increased</td>
<td class="Botrule" align="left" valign="top">4 (0.2)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">59 (31.9)</td>
<td class="Botrule" align="left" valign="top">10 (7.6)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Nervous System</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span></td>
<td class="Botrule" align="left" valign="top">39 (2.4)</td>
<td class="Botrule" align="left" valign="top">13 (2.8)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Skin and Appendages</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule" align="left" valign="top"> 88 (5.3)</td>
<td class="Botrule" align="left" valign="top">20 (4.3)</td>
<td class="Botrule" align="left" valign="top">7 (3.8)</td>
<td class="Botrule" align="left" valign="top">1 (0.8)</td>
<td class="Botrule" align="left" valign="top">3 (1.5)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold">Urogenital</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Kidney function abnormal</span></td>
<td class="Botrule" align="left" valign="top">10 (0.6)</td>
<td class="Botrule" align="left" valign="top">6 (1.3)</td>
<td class="Botrule" align="left" valign="top">40 (21.6)</td>
<td class="Botrule" align="left" valign="top">9 (6.9)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
<td class="Botrule" align="left" valign="top">1 (0.5)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute kidney failure</span></td>
<td class="Botrule" align="left" valign="top">7 (0.4)</td>
<td class="Botrule" align="left" valign="top">2 (0.4)</td>
<td class="Botrule" align="left" valign="top">11 (5.9)</td>
<td class="Botrule" align="left" valign="top">7 (5.3)</td>
<td class="Botrule" align="left" valign="top">0</td>
<td class="Botrule" align="left" valign="top">0</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfb8cf90-0822-4999-939f-764f5eb064be"></a><a name="section-9.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">VISUAL DISTURBANCES</span></h3>
<p class="First">Voriconazole treatment-related <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> are common. In therapeutic trials, approximately 21% of patients experienced <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, color vision change and/or <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>. The <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> were generally mild and rarely resulted in discontinuation. <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span> may be associated with higher plasma concentrations and/or doses.</p>
<p>There have been post-marketing reports of prolonged visual adverse events, including <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>. These events occurred primarily in severely ill patients who had underlying conditions and/or concomitant medications which may have caused or contributed to these events (see <a href="#i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735">WARNINGS</a>).</p>
<p>The mechanism of action of the <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> is unknown, although the site of action is most likely to be within the retina. In a study in healthy subjects investigating the effect of 28-day treatment with voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude, a decrease in the visual field, and an alteration in color perception. The ERG measures electrical currents in the retina. The effects were noted early in administration of voriconazole and continued through the course of study drug dosing. Fourteen days after end of dosing, ERG, visual fields and color perception returned to normal (see <a href="#i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735">WARNINGS</a>, <a href="#i4i_info_patients_id_ab5a8ab6-722a-4535-858f-87e735c078f6">PRECAUTIONS – Information For Patients</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf1172fe-8bf8-4e86-9e41-1d42036dc19c"></a><a name="section-9.2.1.1"></a><p></p>
<h4>Dermatological Reactions</h4>
<p class="First">Dermatological reactions were common in the patients treated with voriconazole. The mechanism underlying these dermatologic adverse events remains unknown. In clinical trials, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> considered related to therapy were reported by 7% (110/1655) of voriconazole-treated patients. The majority of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> were of mild to moderate severity. Cases of <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> appear to be more likely to occur with long-term treatment. Patients have rarely developed serious cutaneous reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> during treatment with VFEND. If patients develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, they should be monitored closely and consideration given to discontinuation of VFEND. It is recommended that patients avoid strong, direct sunlight during VFEND therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c15148dc-be9b-48a5-af5a-bbe89818db66"></a><a name="section-9.3"></a><p></p>
<h2>Less Common Adverse Events</h2>
<p class="First">The following adverse events occurred in &lt; 2% of all voriconazole-treated patients in all therapeutic studies (N=1655). This listing includes events where a causal relationship to voriconazole cannot be ruled out or those which may help the physician in managing the risks to the patients. The list does not include events included in Table 13 above and does not include every event reported in the voriconazole clinical program.</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (see <a href="#i4i_precautions_id_58a12870-2af2-4332-88a5-5090552c23c1">PRECAUTIONS</a>), <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="443216" conceptname="Graft versus host disease">graft versus host reaction</span>, <span class="product-label-link" type="condition" conceptid="4163983" conceptname="Granuloma">granuloma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4318388" conceptname="Injection site infection">injection site infection</span>/<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4318379" conceptname="Disorder of mucous membrane">mucous membrane disorder</span>, multi-organ failure, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">substernal chest pain</span></p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">AV block complete</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">bigeminy</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4217221" conceptname="Nodal rhythm disorder">nodal arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">QT interval prolonged</span>, <span class="product-label-link" type="condition" conceptid="441872" conceptname="Supraventricular premature beats">supraventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (including <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span>)</p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4031954" conceptname="Duodenal ulcer with hemorrhage AND perforation">duodenal ulcer perforation</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcer</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, GGT/LDH elevated, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>, gum <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulcer</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, enlarged liver, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4106572" conceptname="Hypertrophy of parotid gland">parotid gland enlargement</span>, <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span>, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span></p>
<p><span class="Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal cortex insufficiency</span>, <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></p>
<p><span class="Italics">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (macrocytic, megaloblastic, microcytic, normocytic), <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> increased, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, DIC, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="439840" conceptname="Lymphangitis">lymphangitis</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow depression</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, enlarged spleen, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span></p>
<p><span class="Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, BUN increased, creatine phosphokinase increased, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, glucose tolerance decreased, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesteremia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span></p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">bone necrosis</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span></p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">acute brain syndrome</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">brain edema</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Syndrome</span>, <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal convulsion</span>, Guillain-Barré syndrome, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">lung edema</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> syndrome, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span></p>
<p><span class="Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4324123" conceptname="Cutaneous lupus erythematosus">discoid lupus erythematosis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed drug eruption</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4166542" conceptname="Melanosis">melanosis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">skin dry</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">abnormality of accommodation</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="372633" conceptname="Deutan defect">color blindness</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hypoacusis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">night blindness</span>, <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span>, <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span></p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, blighted ovum, creatinine clearance decreased, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4150043" conceptname="Epididymitis">epididymitis</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">kidney pain</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">kidney tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="4230799" conceptname="Edema of scrotum">scrotal edema</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee1c558b-a6c1-441b-b673-b520fe3aafe5"></a><a name="section-9.4"></a><p></p>
<h2>Clinical Laboratory Values</h2>
<p class="First">The overall incidence of clinically significant transaminase abnormalities in all therapeutic studies was 12.4% (206/1655) of patients treated with voriconazole. Increased incidence of liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.</p>
<p>Voriconazole has been infrequently associated with cases of serious hepatic toxicity including cases of <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and rare cases of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of these patients had other serious underlying conditions.</p>
<p>Liver function tests should be evaluated at the start of and during the course of VFEND therapy. Patients who develop <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> during VFEND therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of VFEND must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to VFEND (see <a href="#i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735">WARNINGS</a> and <a href="#i4i_lab_tests_id_a09cb16c-0600-467c-aaf8-ebf93569b576">PRECAUTIONS - Laboratory Tests</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> has been observed in severely ill patients undergoing treatment with VFEND. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and have concurrent conditions that may result in decreased renal function. It is recommended that patients are monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.</p>
<p>Tables 14 and 15 and 16 show the number of patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and clinically significant changes in renal and liver function tests in three randomized, comparative multicenter studies. In study 305, patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> were randomized to either oral voriconazole or oral fluconazole. In study 307/602, patients with definite or probable invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> were randomized to either voriconazole or amphotericin B therapy. In study 608, patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> were randomized to either voriconazole or the regimen of amphotericin B followed by fluconazole.</p>
<a name="id_933e7b32-37e0-4f92-92bf-ba70d808d59e"></a><table width="323.000">
<caption><span>Table 14 Protocol 305 Clinically Significant Laboratory Test Abnormalities</span></caption>
<col align="left" width="20.1%">
<col align="center" width="26.6%">
<col align="center" width="26.6%">
<col align="center" width="26.6%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Criteria<a name="footnote-reference-30" href="#footnote-30" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">Voriconazole</td>
<td class="Botrule" align="left" valign="top">Fluconazole</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">n/N (%)</td>
<td class="Botrule" align="left" valign="top"> n /N (%)</td>
</tr>
</thead>
<tfoot>
<tr><td align="left" colspan="4" valign="top">n          number of patients with a clinically significant abnormality while on study therapy</td></tr>
<tr><td align="left" colspan="4" valign="top">N          total number of patients with at least one observation of the given lab test while on study therapy</td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top">ULN    upper limit of normal</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-30" href="#footnote-reference-30">*</a></dt>
<dd>        Without regard to baseline value</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">T. Bilirubin</td>
<td class="Botrule" align="left" valign="top">&gt;1.5× ULN</td>
<td class="Botrule" align="left" valign="top">8/185 (4.3)</td>
<td class="Botrule" align="left" valign="top">7/186 (3.8)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">AST</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">38/187 (20.3)</td>
<td class="Botrule" align="left" valign="top">15/186 (8.1)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">ALT</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">20/187 (10.7)</td>
<td class="Botrule" align="left" valign="top">12/186 (6.5)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Alk phos</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">19/187 (10.2)</td>
<td class="Botrule" align="left" valign="top">14/186 (7.5)</td>
</tr>
</tbody>
</table>
<a name="id_a63e115b-6139-4a93-a3a6-31c103acaa8a"></a><table width="345.000">
<caption><span>Table 15 Protocol 307/602 Clinically Significant Laboratory Test Abnormalities</span></caption>
<col align="left" width="18.8%">
<col align="center" width="24.9%">
<col align="center" width="24.9%">
<col align="center" width="31.3%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Criteria<a name="footnote-reference-31" href="#footnote-31" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">Voriconazole</td>
<td class="Botrule" align="left" valign="top">Amphotericin B<a name="footnote-reference-32" href="#footnote-32" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">n/N (%)</td>
<td class="Botrule" align="left" valign="top"> n/N (%)</td>
</tr>
</thead>
<tfoot>
<tr><td align="left" colspan="4" valign="top">n          number of patients with a clinically significant abnormality while on study therapy</td></tr>
<tr><td align="left" colspan="4" valign="top">N          total number of patients with at least one observation of the given lab test while on study therapy</td></tr>
<tr><td align="left" colspan="4" valign="top">ULN    upper limit of normal</td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top">LLN     lower limit of normal</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">*</a></dt>
<dd>        Without regard to baseline value</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">†</a></dt>
<dd>        Amphotericin B followed by other licensed antifungal therapy</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">T. Bilirubin</td>
<td class="Botrule" align="left" valign="top">&gt;1.5× ULN</td>
<td class="Botrule" align="left" valign="top">35/180 (19.4)</td>
<td class="Botrule" align="left" valign="top">46/173 (26.6)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">AST</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">21/180 (11.7)</td>
<td class="Botrule" align="left" valign="top">18/174 (10.3)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">ALT</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">34/180 (18.9)</td>
<td class="Botrule" align="left" valign="top">40/173 (23.1)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Alk phos</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">29/181 (16.0)</td>
<td class="Botrule" align="left" valign="top">38/173 (22.0)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Creatinine</td>
<td class="Botrule" align="left" valign="top">&gt;1.3× ULN</td>
<td class="Botrule" align="left" valign="top">39/182 (21.4)</td>
<td class="Botrule" align="left" valign="top">102/177 (57.6)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Potassium</td>
<td class="Botrule" align="left" valign="top">&lt;0.9× LLN</td>
<td class="Botrule" align="left" valign="top">30/181 (16.6)</td>
<td class="Botrule" align="left" valign="top">70/178 (39.3)</td>
</tr>
</tbody>
</table>
<a name="id_1273e8cf-89d2-425c-b4da-e70d954a1dad"></a><table width="345.000">
<caption><span>Table 16 Protocol 608 Clinically Significant Laboratory Test Abnormalities</span></caption>
<col align="left" width="18.8%">
<col align="center" width="24.9%">
<col align="center" width="24.9%">
<col align="center" width="31.3%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Criteria<a name="footnote-reference-33" href="#footnote-33" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">Voriconazole</td>
<td class="Botrule" align="left" valign="top">Amphotericin B followed by Fluconazole</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">n/N (%)</td>
<td class="Botrule" align="left" valign="top"> n/N (%)</td>
</tr>
</thead>
<tfoot>
<tr><td align="left" colspan="4" valign="top">n          number of patients with a clinically significant abnormality while on study therapy</td></tr>
<tr><td align="left" colspan="4" valign="top">N          total number of patients with at least one observation of the given lab test while on study therapy</td></tr>
<tr><td align="left" colspan="4" valign="top">ULN    upper limit of normal</td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top">LLN     lower limit of normal</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-33" href="#footnote-reference-33">*</a></dt>
<dd>        Without regard to baseline value</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">T. Bilirubin</td>
<td class="Botrule" align="left" valign="top">&gt;1.5× ULN</td>
<td class="Botrule" align="left" valign="top">50/261 (19.2)</td>
<td class="Botrule" align="left" valign="top">31/115 (27.0)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">AST</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">40/261 (15.3)</td>
<td class="Botrule" align="left" valign="top">16/116 (13.8)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">ALT</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">22/261 (8.4)</td>
<td class="Botrule" align="left" valign="top">15/116 (12.9)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Alk phos</td>
<td class="Botrule" align="left" valign="top">&gt;3.0× ULN</td>
<td class="Botrule" align="left" valign="top">59/261 (22.6)</td>
<td class="Botrule" align="left" valign="top">26/115 (22.6)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Creatinine</td>
<td class="Botrule" align="left" valign="top">&gt;1.3× ULN</td>
<td class="Botrule" align="left" valign="top">39/260 (15.0)</td>
<td class="Botrule" align="left" valign="top">32/118 (27.1)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Potassium</td>
<td class="Botrule" align="left" valign="top">&lt;0.9× LLN</td>
<td class="Botrule" align="left" valign="top">43/258 (16.7)</td>
<td class="Botrule" align="left" valign="top">35/118 (29.7)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_6b4e7945-aefb-4085-a2ac-99531ea6ca28"></a><a name="section-10"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span></h1>
<p class="First">In clinical trials, there were three cases of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. All occurred in pediatric patients who received up to five times the recommended intravenous dose of voriconazole. A single adverse event of <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> of 10 minutes duration was reported.</p>
<p><span class="Bold">There is no known antidote to voriconazole.</span></p>
<p>Voriconazole is hemodialyzed with clearance of 121 mL/min. The intravenous vehicle, SBECD, is hemodialyzed with clearance of 55 mL/min. In an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, hemodialysis may assist in the removal of voriconazole and SBECD from the body.</p>
<p>The minimum lethal oral dose in mice and rats was 300 mg/kg (equivalent to 4 and 7 times the recommended maintenance dose (RMD), based on body surface area). At this dose, clinical signs observed in both mice and rats included <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, titubation (loss of balance while moving), depressed behavior, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, partially closed eyes, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. Other signs in mice were <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, corneal opacification and swollen abdomen.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_40f5361c-a556-46cc-8ae1-92f7b209c2be"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dbaa9461-5142-4d52-9a50-db6efd38bb8c"></a><a name="section-11.1"></a><p></p>
<h2>Administration</h2>
<p class="First">VFEND Tablets or Oral Suspension should be taken at least one hour before, or one hour following, a meal.</p>
<p>VFEND I.V. for Injection requires reconstitution to 10 mg/mL and subsequent dilution to 5 mg/mL or less prior to administration as an infusion, at a maximum rate of 3 mg/kg per hour over 1–2 hours (see <a href="#i4i_section_id_592edb58-4670-4926-98a7-3808b755a454">Intravenous Administration</a>).</p>
<p><span class="Bold">NOT FOR IV BOLUS INJECTION</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7c074487-3a21-4677-bf88-fd96a5480e3c"></a><a name="section-11.1.1"></a><p></p>
<h3>Use of VFEND I.V. with other Parenteral Drug Products</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31efedda-4929-41bc-8c49-d87fe4a4f9a5"></a><a name="section-11.1.1.1"></a><p></p>
<h4>Blood products and concentrated electrolytes</h4>
<p class="First"><span class="Bold">VFEND I.V. must not be infused concomitantly with any blood product or short-term infusion of concentrated electrolytes, even if the two infusions are running in separate intravenous lines (or cannulas).</span> <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte disturbances</span> such as <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> and <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> should be corrected prior to initiation of VFEND therapy (see <a href="#i4i_precautions_id_58a12870-2af2-4332-88a5-5090552c23c1">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76900906-ac6d-4c5d-a6b6-621062675ac3"></a><a name="section-11.1.1.2"></a><p></p>
<h4>Intravenous solutions containing (non-concentrated) electrolytes</h4>
<p class="First">VFEND I.V. can be infused at the same time as other intravenous solutions containing (non-concentrated) electrolytes, but must be infused through a separate line.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72bb5941-4d37-4a50-8f16-5c842c3875e3"></a><a name="section-11.1.1.3"></a><p></p>
<h4>Total parenteral nutrition (TPN)</h4>
<p class="First">VFEND I.V. can be infused at the same time as total parenteral nutrition, but must be infused in a separate line. If infused through a multiple-lumen catheter, TPN needs to be administered using a different port from the one used for VFEND I.V.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d313495d-3e6c-4806-8514-beebe5268b66"></a><a name="section-11.1.2"></a><p></p>
<h3>Use in Adults</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf586ed1-219f-46d2-b5bc-27a8e5c4e7bd"></a><a name="section-11.1.2.1"></a><p></p>
<h4>Invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> and serious <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> due to Fusarium spp. and Scedosporium apiospermum</h4>
<p class="First">For the treatment of adults with invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Fusarium</span> spp. and <span class="Italics">Scedosporium apiospermum</span>, therapy must be initiated with the specified loading dose regimen of intravenous VFEND to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of high oral bioavailability, switching between intravenous and oral administration is appropriate when clinically indicated (see <a href="#i4i_clinical_pharmacology_id_a7dc4ff3-a754-4ca9-a070-ff5efd1049b0">CLINICAL PHARMACOLOGY</a>). Once the patient can tolerate medication given by mouth, the oral tablet form or oral suspension form of VFEND may be utilized. (See <a href="#id_2ec75a28-e1a6-4898-b97f-82bc2fe9ddcc">Table 17</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7aa40c61-ac9e-4ac7-b676-9dec71d7c627"></a><a name="section-11.1.2.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> in nonneutropenic patients and other deep tissue <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></h4>
<p class="First">See <a href="#id_2ec75a28-e1a6-4898-b97f-82bc2fe9ddcc">Table 17</a>. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c84732f-eb28-4758-898e-178c4959431b"></a><a name="section-11.1.2.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></h4>
<p class="First">See <a href="#id_2ec75a28-e1a6-4898-b97f-82bc2fe9ddcc">Table 17</a>. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.</p>
<a name="id_2ec75a28-e1a6-4898-b97f-82bc2fe9ddcc"></a><table width="430.000">
<caption><span>Table 17: Recommended Dosing Regimen</span></caption>
<col align="center" width="30.0%">
<col align="center" width="30.0%">
<col align="center" width="20.0%">
<col align="center" width="20.0%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Botrule Rrule" align="left" valign="top">Loading dose</td>
<td class="Botrule" align="left" colspan="2" valign="top">Maintenance Dose</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">IV</td>
<td class="Rrule" align="left" valign="top">IV</td>
<td class="Botrule" align="left" valign="top">Oral<a name="footnote-reference-34" href="#footnote-34" class="Sup">*</a>
</td>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-34" href="#footnote-reference-34">*</a></dt>
<dd>Patients who weigh 40 kg or more should receive an oral maintenance dose of 200 mg VFEND every 12 hours. Adult patients who weigh less than 40 kg should receive an oral maintenance dose of 100 mg every 12 hours.</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">†</a></dt>
<dd>In clinical trials, patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> received 3 mg/kg q12h as primary therapy, while patients with other deep tissue <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> received 4 mg/kg as salvage therapy. Appropriate dose should be based on the severity and nature of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
<dt><a name="footnote-36" href="#footnote-reference-36">‡</a></dt>
<dd>Not evaluated in patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"><span class="Bold">Invasive <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">Aspergillosis</span></span></td>
<td class="Botrule" align="left" valign="top">6 mg/kg q12h for the first 24 hours</td>
<td class="Botrule" align="left" valign="top">4 mg/kg q12h</td>
<td class="Botrule" align="left" valign="top">200 mg q12h</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> in nonneutropenic patients and other deep tissue <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span></td>
<td class="Botrule" align="left" valign="top">6 mg/kg q12h for the first 24 hours</td>
<td class="Botrule" align="left" valign="top">3–4 mg/kg q12h <a name="footnote-reference-35" href="#footnote-35" class="Sup">†</a>
</td>
<td class="Botrule" align="left" valign="top">200 mg q12h</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></span></td>
<td class="Botrule" align="left" valign="top"><a name="footnote-reference-36" href="#footnote-36" class="Sup">‡</a></td>
<td class="Botrule" align="left" valign="top"><a href="#footnote-36" class="Sup">‡</a></td>
<td class="Botrule" align="left" valign="top">200 mg q12h</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="Bold">Scedosporiosis and Fusariosis</span></td>
<td class="Botrule" align="left" valign="top">6 mg/kg q12h for the first 24 hours</td>
<td class="Botrule" align="left" valign="top">4 mg/kg q12h</td>
<td class="Botrule" align="left" valign="top">200 mg q12h</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a197dd6f-9575-4548-83bc-b9d0459bbeb3"></a><a name="section-11.1.3"></a><p></p>
<h3>Dosage Adjustment</h3>
<p class="First">If patient response is inadequate, the oral maintenance dose may be increased from 200 mg every 12 hours to 300 mg every 12 hours. For adult patients weighing less than 40 kg, the oral maintenance dose may be increased from 100 mg every 12 hours to 150 mg every 12 hours. If patients are unable to tolerate 300 mg orally every 12 hours, reduce the oral maintenance dose by 50 mg steps to a minimum of 200 mg every 12 hours (or to 100 mg every 12 hours for adult patients weighing less than 40 kg).</p>
<p>If patients are unable to tolerate 4 mg/kg IV, reduce the intravenous maintenance dose to 3 mg/kg every 12 hours.</p>
<p>Phenytoin may be coadministered with VFEND if the intravenous maintenance dose of VFEND is increased to 5 mg/kg every 12 hours, or the oral maintenance dose is increased from 200 mg to 400 mg every 12 hours (100 mg to 200 mg every 12 hours in adult patients weighing less than 40 kg) (see <a href="#i4i_clinical_pharmacology_id_a7dc4ff3-a754-4ca9-a070-ff5efd1049b0">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS - Drug Interactions</a>).</p>
<p>When voriconazole is coadministered with efavirenz, the voriconazole maintenance dose should be increased to 400 mg Q12h and the efavirenz dose should be decreased to 300 mg Q24h. When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see <a href="#i4i_clinical_pharmacology_id_a7dc4ff3-a754-4ca9-a070-ff5efd1049b0">CLINICAL PHARMACOLOGY</a> and <a href="#i4i_interactions_id_c5de75c6-7448-44db-ae9f-1d45661a210d">PRECAUTIONS – Drug Interactions</a>).</p>
<p>Duration of therapy should be based on the severity of the patient's underlying disease, recovery from <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, and clinical response.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_388222fe-0fc5-409b-9f68-f886fc4b4013"></a><a name="section-11.1.3.1"></a><p></p>
<h4>Use in Geriatric Patients</h4>
<p class="First">No dose adjustment is necessary for geriatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30241366-cc30-4c45-9459-9d33d539b472"></a><a name="section-11.1.3.2"></a><p></p>
<h4>Use in Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h4>
<p class="First">In the clinical program, patients were included who had baseline liver function tests (ALT, AST) up to 5 times the upper limit of normal. No dose adjustment is necessary in patients with this degree of abnormal liver function, but continued monitoring of liver function tests for further elevations is recommended (see <a href="#i4i_warnings_id_3089a851-05ef-4c8a-a2cf-c5a4f3e65735">WARNINGS</a>).</p>
<p>It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child-Pugh Class A and B). </p>
<p>VFEND has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child-Pugh Class C) or in patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B or <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> disease. VFEND has been associated with elevations in liver function tests and clinical signs of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, such as <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and should only be used in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> if the benefit outweighs the potential risk. Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> must be carefully monitored for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea8824cf-e26f-4d6f-a724-366a8d0fa635"></a><a name="section-11.1.3.3"></a><p></p>
<h4>Use in Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h4>
<p class="First">The pharmacokinetics of orally administered VFEND are not significantly affected by <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Therefore, no adjustment is necessary for <span class="Underline">oral</span> dosing in patients with mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#i4i_section_id_8979888c-fa68-4cc0-acae-c6eb14ff086d">CLINICAL PHARMACOLOGY - Special Populations</a>).</p>
<p>In patients with moderate or severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance &lt;50 mL/min), accumulation of the intravenous vehicle, SBECD, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the benefit/risk to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients, and, if increases occur, consideration should be given to changing to oral voriconazole therapy (see <a href="#i4i_dosage_admin_id_40f5361c-a556-46cc-8ae1-92f7b209c2be">DOSAGE and ADMINISTRATION</a>).</p>
<p>Voriconazole is hemodialyzed with clearance of 121 mL/min. The intravenous vehicle, SBECD, is hemodialyzed with clearance of 55 mL/min. A 4-hour hemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_592edb58-4670-4926-98a7-3808b755a454"></a><a name="section-11.2"></a><p></p>
<h2>Intravenous Administration</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf3bd5f8-fe34-4563-9eb4-265bc4e23a65"></a><a name="section-11.2.1"></a><p></p>
<h3>VFEND I.V. For Injection</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e355fbe-45df-44c5-83dc-0c3b877c62b2"></a><a name="section-11.2.1.1"></a><p></p>
<h4>Reconstitution</h4>
<p class="First">The powder is reconstituted with 19 mL of Water For Injection to obtain an extractable volume of 20 mL of clear concentrate containing 10 mg/mL of voriconazole. It is recommended that a standard 20 mL (non-automated) syringe be used to ensure that the exact amount (19.0 mL) of Water for Injection is dispensed. Discard the vial if a vacuum does not pull the diluent into the vial. Shake the vial until all the powder is dissolved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_069b5808-b542-4ca8-95e0-39c676e2fa0c"></a><a name="section-11.2.1.2"></a><p></p>
<h4>Dilution</h4>
<p class="First">VFEND must be infused over 1–2 hours, at a concentration of 5 mg/mL or less. Therefore, the required volume of the 10 mg/mL VFEND concentrate should be further diluted as follows (appropriate diluents listed below):</p>
<ol>
<li>Calculate the volume of 10 mg/mL VFEND concentrate required based on the patient's weight (see <a href="#id_1f30a906-d74f-4a95-b5eb-622e95c55b99">Table 18</a>).</li>
<li>In order to allow the required volume of VFEND concentrate to be added, withdraw and discard at least an equal volume of diluent from the infusion bag or bottle to be used. The volume of diluent remaining in the bag or bottle should be such that when the 10 mg/mL VFEND concentrate is added, the final concentration is not less than 0.5 mg/mL nor greater than 5 mg/mL.</li>
<li>Using a suitable size syringe and aseptic technique, withdraw the required volume of VFEND concentrate from the appropriate number of vials and add to the infusion bag or bottle. <span class="Bold">Discard Partially Used Vials.</span>
</li>
</ol>
<p>The final VFEND solution must be infused over 1–2 hours at a maximum rate of 3 mg/kg per hour.</p>
<a name="id_1f30a906-d74f-4a95-b5eb-622e95c55b99"></a><table width="344.000">
<caption><span>Table 18: Required Volumes of 10 mg/mL VFEND Concentrate</span></caption>
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" rowspan="2" valign="bottom">Body Weight<br>(kg)</td>
<td class="Botrule" align="left" colspan="3" valign="top">Volume of VFEND Concentrate (10 mg/mL) required for:</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">3 mg/kg dose<br>(number of vials)</td>
<td class="Rrule" align="left" valign="top">4 mg/kg dose<br>(number of vials)</td>
<td class="Botrule" align="left" valign="top">6 mg/kg dose<br>(number of vials)</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">30</td>
<td class="Botrule" align="left" valign="top">9.0 mL (1)</td>
<td class="Botrule" align="left" valign="top">12 mL (1)</td>
<td class="Botrule" align="left" valign="top">18 mL (1)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">35</td>
<td class="Botrule" align="left" valign="top">10.5 mL (1)</td>
<td class="Botrule" align="left" valign="top">14 mL (1)</td>
<td class="Botrule" align="left" valign="top">21 mL (2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">40</td>
<td class="Botrule" align="left" valign="top">12.0 mL (1)</td>
<td class="Botrule" align="left" valign="top">16 mL (1)</td>
<td class="Botrule" align="left" valign="top">24 mL (2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">45</td>
<td class="Botrule" align="left" valign="top">13.5 mL (1)</td>
<td class="Botrule" align="left" valign="top">18 mL (1)</td>
<td class="Botrule" align="left" valign="top">27 mL (2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">50</td>
<td class="Botrule" align="left" valign="top">15.0 mL (1)</td>
<td class="Botrule" align="left" valign="top">20 mL (1)</td>
<td class="Botrule" align="left" valign="top">30 mL (2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">55</td>
<td class="Botrule" align="left" valign="top">16.5 mL (1)</td>
<td class="Botrule" align="left" valign="top">22 mL (2)</td>
<td class="Botrule" align="left" valign="top">33 mL (2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">60</td>
<td class="Botrule" align="left" valign="top">18.0 mL (1)</td>
<td class="Botrule" align="left" valign="top">24 mL (2)</td>
<td class="Botrule" align="left" valign="top">36 mL (2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">65</td>
<td class="Botrule" align="left" valign="top">19.5 mL (1)</td>
<td class="Botrule" align="left" valign="top">26 mL (2)</td>
<td class="Botrule" align="left" valign="top">39 mL (2)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">70</td>
<td class="Botrule" align="left" valign="top">21.0 mL (2)</td>
<td class="Botrule" align="left" valign="top">28 mL (2)</td>
<td class="Botrule" align="left" valign="top">42 mL (3)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">75</td>
<td class="Botrule" align="left" valign="top">22.5 mL (2)</td>
<td class="Botrule" align="left" valign="top">30 mL (2)</td>
<td class="Botrule" align="left" valign="top">45 mL (3)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">80</td>
<td class="Botrule" align="left" valign="top">24.0 mL (2)</td>
<td class="Botrule" align="left" valign="top">32 mL (2)</td>
<td class="Botrule" align="left" valign="top">48 mL (3)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">85</td>
<td class="Botrule" align="left" valign="top">25.5 mL (2)</td>
<td class="Botrule" align="left" valign="top">34 mL (2)</td>
<td class="Botrule" align="left" valign="top">51 mL (3)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">90</td>
<td class="Botrule" align="left" valign="top">27.0 mL (2)</td>
<td class="Botrule" align="left" valign="top">36 mL (2)</td>
<td class="Botrule" align="left" valign="top">54 mL (3)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">95</td>
<td class="Botrule" align="left" valign="top">28.5 mL (2)</td>
<td class="Botrule" align="left" valign="top">38 mL (2)</td>
<td class="Botrule" align="left" valign="top">57 mL (3)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">100</td>
<td class="Botrule" align="left" valign="top">30.0 mL (2)</td>
<td class="Botrule" align="left" valign="top">40 mL (2)</td>
<td class="Botrule" align="left" valign="top">60 mL (3)</td>
</tr>
</tbody>
</table>
<p>VFEND I.V. for Injection is a single dose unpreserved sterile lyophile. Therefore, from a microbiological point of view, once reconstituted, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2° to 8°C (36° to 46°F). This medicinal product is for single use only and any unused solution should be discarded. Only clear solutions without particles should be used.</p>
<p>The reconstituted solution can be diluted with:</p>
<p>9 mg/mL (0.9%) Sodium Chloride USP</p>
<p>Lactated Ringers USP</p>
<p>5% Dextrose and Lactated Ringers USP</p>
<p>5% Dextrose and 0.45% Sodium Chloride USP </p>
<p>5% Dextrose USP</p>
<p>5% Dextrose and 20 mEq Potassium Chloride USP</p>
<p>0.45% Sodium Chloride USP</p>
<p>5% Dextrose and 0.9% Sodium Chloride USP </p>
<p>The compatibility of VFEND I.V. with diluents other than those described above is unknown (see <a href="#i4i_section_id_bd062b63-a568-439c-94c2-dd7e73a53c8d">Incompatibilities</a> below).</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd062b63-a568-439c-94c2-dd7e73a53c8d"></a><a name="section-11.2.1.3"></a><p></p>
<h4>Incompatibilities</h4>
<p class="First">VFEND I.V. must not be diluted with 4.2% Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Infusion. The mildly alkaline nature of this diluent caused slight degradation of VFEND after 24 hours storage at room temperature. Although refrigerated storage is recommended following reconstitution, use of this diluent is not recommended as a precautionary measure. Compatibility with other concentrations is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e13f446-90ba-4a2d-b1d8-7724803921c5"></a><a name="section-11.2.2"></a><p></p>
<h3>VFEND for Oral Suspension</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af37d9bc-6750-43c4-ae12-28d06923b25d"></a><a name="section-11.2.2.1"></a><p></p>
<h4>Reconstitution</h4>
<p class="First">Tap the bottle to release the powder. Add 46 mL of water to the bottle. Shake the closed bottle vigorously for about 1 minute. Remove child-resistant cap and push bottle adaptor into the neck of the bottle. Replace the cap. Write the date of expiration of the reconstituted suspension on the bottle label (the shelf-life of the reconstituted suspension is 14 days at controlled room temperature 15–30°C [59–86°F]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aeb0abb6-a7f1-46fd-9297-1aba53ebed13"></a><a name="section-11.2.2.2"></a><p></p>
<h4>Instructions for use</h4>
<p class="First">Shake the closed bottle of reconstituted suspension for approximately 10 seconds before each use. The reconstituted oral suspension should only be administered using the oral dispenser supplied with each pack. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e6da750-6537-41b0-bd2a-05ec2c0d0a24"></a><a name="section-11.2.2.3"></a><p></p>
<h4>Incompatibilities</h4>
<p class="First">VFEND for Oral Suspension and the 40 mg/mL reconstituted oral suspension should not be mixed with any other medication or additional flavoring agent. It is not intended that the suspension be further diluted with water or other vehicles.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_7de0fd15-af2e-4cdf-b899-d350cdcaaaf9"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Powder for Solution for Injection</span></p>
<p>VFEND I.V. for Injection is supplied in a single use vial as a sterile lyophilized powder equivalent to 200 mg VFEND and 3200 mg sulfobutyl ether beta-cyclodextrin sodium (SBECD).</p>
<p>Individually packaged vials of 200 mg VFEND I.V.<br>      (NDC 0049-3190-28)</p>
<p><span class="Bold">Tablets</span></p>
<p>VFEND 50 mg tablets; white, film-coated, round, debossed with "Pfizer" on one side and "VOR50" on the reverse.<br>     Bottles of 30 (NDC 0049-3170-30) </p>
<p>VFEND 200 mg tablets; white, film-coated, capsule shaped, debossed with "Pfizer" on one side and "VOR200" on the reverse.<br>     Bottles of 30 (NDC 0049-3180-30)</p>
<p><span class="Bold">Powder for Oral Suspension</span></p>
<p>VFEND for Oral Suspension is supplied in 100 mL high density polyethylene (HDPE) bottles. Each bottle contains 45 g of powder for oral suspension. Following reconstitution, the volume of the suspension is 75 mL, providing a usable volume of 70 mL (40 mg voriconazole/mL). A 5 mL oral dispenser and a press-in bottle adaptor are also provided.<br>     (NDC 0049-3160-44)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_89575a60-6398-45c8-b41f-aef5c9e8d07d"></a><a name="section-12.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">VFEND I.V. for Injection unreconstituted vials should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature]. VFEND is a single dose unpreserved sterile lyophile. From a microbiological point of view, following reconstitution of the lyophile with Water for Injection, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2° to 8°C (36° to 46°F). Chemical and physical in-use stability has been demonstrated for 24 hours at 2° to 8°C (36° to 46°F). This medicinal product is for single use only and any unused solution should be discarded. Only clear solutions without particles should be used (see <a href="#i4i_section_id_592edb58-4670-4926-98a7-3808b755a454">DOSAGE AND ADMINISTRATION - Intravenous Administration</a>).</p>
<p>VFEND Tablets should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature].</p>
<p>VFEND Powder for Oral Suspension should be stored at 2° – 8°C (36° – 46° F) (in a refrigerator) before reconstitution. The shelf-life of the powder for oral suspension is 18 months. </p>
<p>The reconstituted suspension should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze. Keep the container tightly closed. The shelf-life of the reconstituted suspension is 14 days. Any remaining suspension should be discarded 14 days after reconstitution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_9623634b-bed5-4f67-945e-5a465ce0d6bb"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved Standard M38-P. Clinical Laboratory Standards Institute, Villanova, Pa.</li>
<li>Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A. Clinical Laboratory Standards Institute, Villanova, Pa.</li>
<li>Clinical Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved guideline M44-A. Clinical Laboratory Standards Institute, Villanova, Pa.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c065f7d-c440-4676-8ca0-ab37b9211116"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-02.jpg"></p>
<p>LAB-0271-22.0</p>
<p>May 2008</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_ccbb8242-587c-4fd4-8066-58dd494b8a4b"></a><a name="section-15"></a><p></p>
<h1>PATIENT INFORMATION<br>VFEND <span class="Sup">®</span> (VEE-fend)<br>(voriconazole IV injection, tablets, liquid)</h1>
<p class="First">Read the Patient Information that comes with VFEND before you start taking it and each time you get a refill. There may be new information. This information does not replace talking with your doctor about your condition or treatment. </p>
<p><span class="Bold">What is VFEND?</span></p>
<p>VFEND is a prescription medicine that treats certain serious <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> in your blood and body; these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are called "<span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>," "<span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>," "<span class="Italics">Scedosporium,</span>" "<span class="Italics">Fusarium,</span>" and "<span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>.".</p>
<p>VFEND is for adults and children over 12 years of age.</p>
<p><span class="Bold">What should I tell my doctor before taking VFEND?</span></p>
<p>Tell your doctor about all your health conditions, including if you: </p>
<ul>
<li>
<span class="Bold">have or ever had an abnormal heart rate or rhythm.</span> Your doctor may order a test to check your heart (EKG) before starting VFEND.</li>
<li>
<span class="Bold">have liver or kidney problems.</span> Your doctor may do blood tests to make sure you can take VFEND.</li>
<li>
<span class="Bold">have trouble digesting dairy products, lactose, or regular table sugar. VFEND tablets</span> contain lactose (milk sugar). <span class="Bold">VFEND liquid</span> contains sucrose (table sugar).</li>
<li>
<span class="Bold">had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to any other medicine</span>, such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face or throat.</li>
<li>
<span class="Bold">are pregnant or planning to become pregnant while taking this medication. VFEND can harm your unborn baby.</span> Women who can become pregnant should use effective birth control while taking VFEND.</li>
<li>
<span class="Bold">are breast-feeding.</span> It is not known if VFEND passes into breast milk. You and your doctor will need to decide if VFEND is right for you while you are nursing.</li>
</ul>
<p>Know what medications you are taking. Be sure to tell your doctor about all the medications that you are taking, including prescription medicines, non-prescription medicines, vitamins, and herbal remedies. Keep a list of them with you to show your doctor or pharmacist.</p>
<p><span class="Bold">Who should not take VFEND?</span></p>
<p>Do NOT take VFEND if you are taking the medicines listed below. Serious or life-threatening side effects from these medicines, or a decrease in the effect of VFEND could result if any of these medicines are taken together with VFEND. Tell your doctor right away if you are taking any of these medications:</p>
<ul>
<li>terfenadine (Seldane<span class="Sup">®</span>) </li>
<li>astemizole (Hismanal<span class="Sup">®</span>)</li>
<li>cisapride (Propulsid<span class="Sup">®</span>)</li>
<li>pimozide (Orap<span class="Sup">®</span>)</li>
<li>sirolimus (Rapamune<span class="Sup">®</span>)</li>
<li>carbamazepine (Tegretol<span class="Sup">®</span>)</li>
<li>rifampin (Rifadin<span class="Sup">®</span>)</li>
<li>rifabutin (Mycobutin<span class="Sup">®</span>)</li>
<li>St. John's Wort (herbal supplement)</li>
<li>quinidine (like Quinaglute<span class="Sup">®</span>)</li>
<li>ergotamine, dihydroergotamine, methysergide (Sansert<span class="Sup">®</span>), and bromocriptine (Parlodel<span class="Sup">®</span>) </li>
<li>long-acting barbiturates like phenobarbital (Luminal<span class="Sup">®</span>)</li>
<li>ritonavir (Norvir®) and efavirenz (Sustiva<span class="Sup">®</span>) (Some doses of ritonavir and efavirenz can be taken at the same time as VFEND, but you must check with your doctor first)</li>
</ul>
<p>If you have questions or are uncertain about your medications, talk with your doctor or pharmacist.</p>
<p>Do not take VFEND if you are allergic to anything in it. The active ingredient is voriconazole. There is a list of what is in VFEND at the end of this leaflet.</p>
<p><span class="Bold">Can I take other medicines with VFEND?</span></p>
<p>VFEND and many medicines can interact with each other and some should not be taken together (see "Who should not take VFEND?"). Other medicines may need the dose adjusted when taken with Vfend. Knowing the medicines that you are taking is important. <span class="Bold">Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins and herbal supplements. Keep a list of them with you to show your doctor or pharmacist. Do not take any new medicine without talking with your doctor.</span></p>
<p><span class="Bold">How do I take VFEND?</span></p>
<ul>
<li>VFEND comes in I.V. (intravenous) form, or as a tablet or liquid.</li>
<li>
<span class="Bold">VFEND I.V.</span> Your doctor or nurse may give you VFEND through a needle in your vein (intravenous, I.V.). It takes 1 to 2 hours to get each dose.</li>
<li>
<span class="Bold">VFEND tablets.</span> Take the tablets as your doctor tells you. Take your dose at least 1 hour before or at least 1 hour after meals.</li>
<li>
<span class="Bold">VFEND liquid</span>. Take the liquid as your doctor tells you. Take it at least 1 hour before or at least 1 hour after meals.</li>
<li>VFEND is usually taken every 12 hours. Follow your doctor's instructions on when to take it. If you miss a dose of VFEND, take it as soon as you remember. If it is more than 6 hours since you missed your dose, <span class="Underline">wait</span>. Do not take the missed dose. Take VFEND at the next regular dosing time. Do not take double doses.</li>
<li>If you take too much VFEND or develop serious reactions, call your doctor or poison control center, or go to the nearest emergency room.</li>
</ul>
<p><span class="Bold">What should I avoid while taking VFEND?</span></p>
<dl>
<dt> </dt>
<dd>Avoid night driving, because VFEND may cause vision problems like <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurry vision</span>.</dd>
<dt> </dt>
<dd>Avoid all driving or using dangerous machinery, <span class="Bold">if</span> you have any change in your eyesight.</dd>
<dt> </dt>
<dd>Avoid bright sunlight. Your skin may burn more easily. Your eyes may hurt in bright sunlight.</dd>
</dl>
<p><span class="Bold">What are possible side effects of VFEND?</span></p>
<p><span class="Bold">VFEND may cause serious or life threatening side effects. Call your doctor right away if you have any of the following symptoms:</span></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Serious changes in heart rate or rhythm,</span> including heart stopping (<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>). People who have certain heart conditions or who take certain other medicines have a higher chance for this problem.</dd>
<dt> </dt>
<dd>
<span class="Bold">Eyesight (vision) changes.</span> These changes include <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, color vision change, and being sensitive to light while you are taking VFEND. These changes are generally mild. Vision side effects lasting for more than one month have been reported by some patients. Your doctor should monitor your eyesight if you take VFEND for more than 28 days.</dd>
<dt> </dt>
<dd>
<span class="Bold">Liver problems.</span> VFEND can cause liver problems that usually go away when you stop VFEND. It can also cause very serious liver problems. Your doctor should test your liver function while you are taking VFEND. Call your doctor if you have any of these symptoms of liver problems, you: <ul>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span>, or your skin or eyes turn yellow</li>
<li>feel more tired than usual</li>
<li>feel like you have the flu</li>
<li>have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
</dd>
<dt> </dt>
<dd>
<span class="Bold">Kidney problems.</span> Your doctor may check your kidney function while you are taking VFEND. Your doctor will decide if you can keep taking it or if you need a lower dose. Call your doctor if you have any of these symptoms of kidney problems: <ul><li>no appetite, feeling very tired</li></ul>
</dd>
<dt> </dt>
<dd>changes in thinking, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or trouble breathing</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt> </dt>
<dd>
<span class="Italics">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span> <span class="Bold"><span class="Italics">can happen with VFEND injection. These include <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, fast heartbeats, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, trouble breathing, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Your doctor should stop your VFEND infusion if you have any of these symptoms.</span></span>
</dd>
<dt> </dt>
<dd>
<span class="Italics">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span> <span class="Bold"><span class="Italics">If you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, sores in your mouth, or your skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and peels, stop using VFEND. Call your doctor right away.</span></span>
</dd>
</dl>
<p>Common side effects with VFEND include eyesight changes, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in your blood, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your arms and legs, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pains</span>, and breathing problems. </p>
<p>These are not all the side effects with VFEND. For more information, ask your doctor or pharmacist.</p>
<p><span class="Bold">How do I store VFEND?</span></p>
<ul>
<li>Store VFEND tablets and liquid at room temperature, 59° to 86° F (15°to 30°C). Do not refrigerate or freeze. The liquid should be discarded after 14 days. Keep all containers tightly closed. </li>
<li>I.V. VFEND should be given by your nurse or doctor.</li>
<li><span class="Bold">Keep VFEND, as well as all other medicines, out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General information about VFEND</span></p>
<p>Doctors can prescribe medicines for conditions that are not in this leaflet. Use VFEND only for what your doctor prescribed. Do not give it to other people, even if they have the same symptoms you have. It may harm them. </p>
<p>This leaflet gives the most important information about VFEND. For more information, talk with your doctor. You can ask your doctor or pharmacist for information about VFEND that is written for health professionals. </p>
<p><span class="Bold">What is in VFEND?</span></p>
<p>Active ingredient: voriconazole<br>Inactive ingredients:<br><span class="Bold">VFEND IV:</span> sulfobutyl ether beta-cyclodextrin sodium</p>
<p><span class="Bold">VFEND tablets:</span> lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesium stearate, and a coating containing hypromellose, titanium dioxide, lactose monohydrate, and triacetin </p>
<p><span class="Bold">VFEND liquid:</span> colloidal silicon dioxide, titanium dioxide, xanthan gum, sodium citrate dihydrate, sodium benzoate, anhydrous citric acid, natural orange flavor, and sucrose</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-03.jpg"></p>
<p><span class="Bold">Rx Only</span></p>
<p>Trademarks are the property of their respective owners.</p>
<p>LAB-0311-5.0<br>March 2008</p>
<p>VFEND 50 mg and 200 mg tablets are available from Cardinal Health in unit dose packages of 30.</p>
<p>50 mg, unit dose package of 30 tablets, NDC 55154-2730-4</p>
<p>200 mg, unit dose package of 30 tablets, NDC 55154-2725-4</p>
<p>Cardinal Health</p>
<p>Zanesville OH 43701 </p>
<p>IU37363861109</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1b6a4091-b044-49bf-b191-c022b905aa73"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel - 50 mg Carton</h1>
<p class="First">Vfend<span class="Sup">®</span></p>
<p>(voriconazole)</p>
<p>50 mg</p>
<p>30 Tablets</p>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5a87dde2-590a-4d2f-be98-25d96fd82346"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel - 50 mg Pouch</h1>
<p class="First">Vfend<span class="Sup">®</span></p>
<p>(voriconazole)</p>
<p>50 mg</p>
<p>Tablets</p>
<div class="Figure"><img alt="Pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f8d05e31-f954-41ae-87d0-614ed38f4db7"></a><a name="section-18"></a><p></p>
<h1><span class="Bold">Principal Display Panel - 50 mg Bag</span></h1>
<p class="First">Vfend<span class="Sup">®</span> 50 MG</p>
<p>Voriconazole Tablets</p>
<p>10 Tablets</p>
<div class="Figure"><img alt="Bag Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_6163ee76-0695-4e1e-a211-b0dcbf1d96b1"></a><a name="section-19"></a><p></p>
<h1>Principal Display Panel - 200 mg Carton</h1>
<p class="First">Vfend<span class="Sup">®</span></p>
<p>(voriconazole)</p>
<p>200 mg</p>
<p>30 Tablets</p>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0a6fada0-0ef5-423a-b5fa-0069d6b74830"></a><a name="section-20"></a><p></p>
<h1>Principal Display Panel - 200 mg Pouch</h1>
<p class="First">Vfend<span class="Sup">®</span></p>
<p>(voriconazole)</p>
<p>200 mg</p>
<p>Tablets</p>
<div class="Figure"><img alt="Pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_931c73f3-097c-48c2-b062-2b516ed79773"></a><a name="section-21"></a><p></p>
<h1><span class="Bold">Principal Display Panel - 200 mg Bag</span></h1>
<p class="First">Vfend<span class="Sup">®</span> 200 MG</p>
<p>Voriconazole Tablets</p>
<p>10 Tablets</p>
<div class="Figure"><img alt="Bag Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac3e3964-90c0-44dd-800c-ec9606629572&amp;name=d8221a13-334f-47d6-9333-0add270f6288-09.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VFEND 		
					</strong><br><span class="contentTableReg">voriconazole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-2730(NDC:0049-3170)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>voriconazole</strong> (voriconazole) </td>
<td class="formItem">voriconazole</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;VOR50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2730-4</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2730-6</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-2730-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021266</td>
<td class="formItem">05/24/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VFEND 		
					</strong><br><span class="contentTableReg">voriconazole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-2725(NDC:0049-3180)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>voriconazole</strong> (voriconazole) </td>
<td class="formItem">voriconazole</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;VOR200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2725-4</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2725-6</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-2725-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021266</td>
<td class="formItem">05/24/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-2730, 55154-2725)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d8221a13-334f-47d6-9333-0add270f6288</div>
<div>Set id: ac3e3964-90c0-44dd-800c-ec9606629572</div>
<div>Version: 2</div>
<div>Effective Time: 20111110</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
